Doctor of Philosophy by Smith, Thomas E.
INTEGRATED APPROACHES FOR THE DISCOVERY AND PRODUCTION OF  
 














A dissertation submitted to the faculty of 
The University of Utah 












Department of Medicinal Chemistry 
 
The University of Utah 
 
December 2016 
Copyright © Thomas E. Smith 2016 
 
All Rights Reserved 








The dissertation of Thomas E. Smith 
has been approved by the following supervisory committee members: 
 
Eric W. Schmidt , Chair 10/17/2016 
 
Date Approved 
Chris M. Ireland , Member 10/17/2016 
 
Date Approved 
Amy M. Barrios , Member 10/17/2016 
 
Date Approved 
Louis R. Barrows , Member 10/17/2016 
 
Date Approved 




and by Kristen A. Keefe , Chair/Dean of  
the Department/College/School of Pharmacy 
 







 Natural products are structurally complex molecules and often exhibit intriguing 
biological activities. They are, however, notoriously difficult to supply, whether by 
chemical synthesis or isolation from a living organism. Recently, reconstitution of natural 
product biosynthetic pathways in a heterologous host has proved a successful strategy for 
producing natural products in vivo, but has rarely achieved the level of sustainability 
desired for medicinal applications. This approach is limited by our lack of understanding 
of biosynthesis and pathway expression. The focus of this dissertation is biosynthetic 
strategies for the supply of therapeutically-relevant natural products. Two examples are 
included, one involving a biosynthetic outlook of a known family of compounds with an 
uncharacterized metabolic origin, and a second uniting discovery, production, and 
biological characterization of a novel anti-HIV compound. 
The adociasulfates are a family of marine sponge-derived meroterpenes known to 
inhibit kinesin, making them attractive anticancer drug leads. Despite difficulties in 
synthesizing adociasulfates, biosynthesis has never been investigated as a potential means 
of production. In Chapter 1, detailed consideration is given to the biosynthetic origin of 
these compounds, revealing a set of just four possible precursors for all sponge 
merotriterpenes. The mechanism of action of adociasulfates, addressed in Chapter 2, was 
shown to occur in a 1:1 interaction with kinesin, contrary to previous reports of 
microtubule-mimicking aggregates. Adociasulfates are thus shown to be valuable tools 
 iv 
for the study of kinesin and maintain potential therapeutic importance, making their 
production an ever more important goal.  
The discovery, production, and biological characterization of an anti-HIV 
lanthipeptide, divamide A, is described in Chapter 3. The divamides were discovered 
from small tunicates from Papua New Guinea. By integrating structure- and genomics-
based methodologies, we were able to elucidate the structure of a small amount of 
isolated material. This approach also provided us with a biosynthetic platform from 
which heterologous expression and sustainable production were achieved in Escherichia 
coli. The structure activity relationships of the divamides show that functional diversity is 
achieved by introducing minor structural changes to a conserved chemical scaffold 
Finally, an extended family of related peptides was identified that bears some of the 
hallmarks of known diversity-generating pathways. 
Yeah this one right here goes out to all the baby's mamas, mamas 
Mamas, mamas, baby mamas, mamas 
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INTRODUCTION – A PRELIMINARY INVESTIGATION OF THE BIOSYNTHESIS 
 





 Kinesins are an attractive drug target for their role in both intracellular vesicle 
transport and cell division. While a number of kinesin inhibitors exist that target the site 
of ATP hydrolysis, only one family of compounds, the sponge-derived adociasulfates, 
inhibits kinesin competitively for microtubule-binding. Access to these compounds, 
however, is extremely limited. Thus, a sustainable means of producing adociasulfates is 
necessary in order to make full use of their potential. In this review, a biogenetic 
hypothesis is presented, highlighting several key structural features that provide clues to 
the metabolic origin of the adociasulfates. These clues suggest a bacterial source, 
although this has yet to be investigated. Additionally, the adociasulfates appear to be 
derived from at least four different hydroquinone hexaprenyl diphosphate precursors, 
each varying in number and position of epoxidations. A hypothetical biosynthetic 
pathway was reconstructed that may aid in the discovery of the authentic pathway from 
the sponge metagenome, with the intention of reconstituting this pathway for 
adociasulfate production. A similar rationale can be extended to other sponge 
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meroterpenoids, many of which display unique bioactivities, but all of which lack 
characterization of their respective biosynthetic pathways. 
 
1.2 Introduction to kinesins 
 Kinesin motor proteins perform essential functions in eukaryotes, all involving 
the movement of motor domains along microtubule (MT) filaments. They regulate 
intracellular trafficking of vesicles and organelles, leading to roles in establishing cell 
polarity, development, and higher brain function.1 They are also involved in cell division, 
where they are responsible for assembly and separation of the mitotic spindle.2 As a 
result, inhibitors of kinesins are highly sought after, both as probes of molecular motor 
function and as drug leads. Kinesin superfamily (KIF) proteins each contain two motor 
domains, each of which has two regions considered to be druggable: the MT-binding 
domain and the motor domain. Kinesin motor domains couple the hydrolysis of ATP to 
conformational changes that translate into a stepping-like motion. Iterative rounds of 
ATP hydrolysis result in “walking” along an MT. The cycle of MT binding and ATP 
hydrolysis involves a weakly MT-binding state defined by bound ADP, and a strongly 
MT-binding state in which ATP is hydrolyzed.3 Between these two states, binding of 
ADP-bound motor domains to MTs induces release of ADP and allows for the binding of 
ATP, while hydrolysis of ATP and release of phosphate allows the motor protein to 
assume the weakly MT-binding state once more. The cycles of hydrolysis of the two 
motor domains are staggered, such that an ATP-bound domain remains anchored to the 
MT while the ADP-bound domain releases the MT during the “step.” The MT-binding 
region is not catalytic and simply serves as the binding site for MTs.  
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1.3 A mechanism of kinesin inhibition unique to adociasulfates 
To date, adociasulfates remain the only known natural product kinesin inhibitors 
that compete with MTs for binding. All other known kinesin inhibitors, natural or 
synthetic, interfere with the ATPase function of kinesin either by direct competition with 
ATP or via an allosteric effect. Exceptions include the fluorescein analogue rose bengal 
lactone (RBL) and the polyoxometalate (POM) NSC 622124 ([K6Mo18O62P2]6–) (Figure 
1.1).4-5 These inhibitors, though potent, display characteristic features of nonspecific 
inhibition, including a propensity to form aggregates, bind indiscriminately to positively 
charged protein surfaces, and inhibition of a variety of enzyme activities.  
RBL was initially identified as a kinesin inhibitor in a computational docking 
screen for kinesin ligands, where it was shown to prevent MT binding by kinesin and 
inhibit both basal and MT-stimulated ATPase activity in the low micromolar IC50 range.4 
The RBL binding site was even mapped to the MT-binding domain of kinesin using 
docking and FRET techniques, implying its mode of binding was analogous to that of 
adociasulfate-2.6 The designation of RBL as a kinesin inhibitor hit was later exposed as a 
false positive on the basis that RBL forms large, 300-500 nm diameter particles and acts 
as a nonspecific inhibitor of various enzyme activities.8 RBL also blocks the binding of 
myosin to actin within the mid-micromolar range, calling into question its potential as a 
tool to probe molecular motor function.4 Despite this, recent cell-based research has 
employed RBL to study kinesin in vitro and in vivo.9-10 It is difficult to draw concrete 
conclusions from biological applications of RBL while controversies exist over its 
specificity, but perhaps more distressing is that these controversies go largely unnoticed 
by the broader scientific community.  
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NSC 622124 is a negatively-charged, achiral, nanometer-scale particle that 
inhibits both basal and MT-stimulated ATPase activity of a variety of kinesins with mid-
nanomolar IC50 values.5 The NSC 622124 binding site maps to two regions of kinesin, 
one that occurs within the MT-binding domain and the other nearby the nucleotide-
binding domain. While NSC 622124 is encouragingly potent, a number of features 
suggest that it has limited usefulness. While adociasulfates and RBL can be classified as 
small molecules, NSC 622124 is large (MW >3000 Da), anionic and membrane 
impermeable.7 NSC 622124 is a nanomolar inhibitor of a variety of unrelated proteins in 
addition to kinesin, including CK2, GSKß, and c-Src kinases, and DNA-binding by Sox-
2.7, 11 Charged surface residues mediate these interactions, without which NSC 622124 
inhibition is impaired.5, 7, 11 NSC 622124 is unstable and is readily hydrolyzed in aqueous 
environments, but the addition of nontarget protein enhances its lifetime and maintains its 
activity.7 These observations suggest that off-target protein interactions do occur. There 
is also the potential for a large, achiral molecule to bind multiple copies of a target. 
Indeed, aggregations of NSC 622124 with target protein have been observed at low 
micromolar NSC 622124 concentrations.7 While there is clear evidence that each POM 
exhibits selectivity for distinct targets and maintains unique structure-activity 
relationships, there is a propensity for NSC 622124, and likely for other POMs, to bind 
multiple targets with significant efficiencies. Collectively, use of NSC 622124 may yield 
misleading information with regard to target function in vivo.  
Until recently, adociasulfates were thought to form MT-mimicking aggregates, 
bringing into question their potential as drugs or mechanistic probes.12 It is now 
understood that adociasulfates bind kinesin in a 1:1 interaction.13 In light of these 
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findings, it is crucial to point out the unlikeliness of kinesin inhibitors RBL and NSC 
622124 to behave as expected in biochemical or cell-based investigations. Adociasulfates 
are the only experimentally validated inhibitors to compete with MTs for binding kinesin 
at a single-molecule level. Thus, there exists some urgency to achieve sustainable 
adociasulfate production. In this chapter, I have laid out a strategy to identify the 
biosynthetic pathway responsible for adociasulfate production in the sponge holobiont 
based on a proposed biosynthetic route, highlighting several distinguishing features of 
these molecules. With knowledge of the adociasulfate biosynthesis available, production 
might be achieved in vitro by pathway reconstitution or in vivo by heterologous 
expression. 
 
1.4 A proposed biosynthetic route for sponge merotriterpenoids 
 Adociasulfates are part of a large family of sponge-derived meroterpenoids. 
Along with related triterpene hydroquinones, adociasulfates appear to be restricted to 
sponges within the Chalinidae family, specifically members of the Haliclona and 
Cladocroce genera (Figure 1.2).6, 13-18 Merosesquiterpenoids encompass a much greater 
diversity of compounds than merotriterpenoids and can be found in a diverse range of 
sponge lineages, especially within the genus Dysidea.19 Diterpene and sesterterpene 
hydroquinones have also been isolated from sponges.20-21 A recent and comprehensive 
review of sponge meroterpenoids highlights the structural diversity and biological 
activity of this extensive class of compounds.19 Here, I will point out distinctive features 
of the adociasulfate structure indicative of their biogenetic origin. These features have 
broad implications for sponge meroterpenoid biosynthesis in general. As will become 
evident in the following discussion, there are many overlapping structural features of 
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meroterpenoids that suggest a common metabolic origin. However, there is a lack of 
knowledge with regard to meroterpenoid biosynthesis by sponges or their associated 
bacteria. No pathways for such compounds have been described despite hundreds of 
known compounds. The characterization of one meroterpenoid pathway could shed light 
on other pathways responsible for the production of bioactive molecules, some of which 
have known mechanisms of action and exhibit unique activities that cannot be substituted 
using any readily available compounds.13, 22-23 Adociasulfates provide an excellent 
starting point because a relatively simple biosynthetic hypothesis can be postulated, with 
few enzymatic steps leading to the construction of the carbon skeleton and a limited 
number of potential hydrobenzoquinoid precursors. In fact, it is conceivable that all 
sponge triterpene hydroquinols are derived from a single parent pathway. Below, I will 
discuss the features that unify the adociasulfates and their ilk, establish a biogenetic 
hypothesis, and provide a hypothetical, bacterial adociasulfate pathway based on these 
observations. 
 A defining feature of the adociasulfates is the requirement for a linear triterpene-
diphosphate as opposed to a precursor derived from squalene. Prenyl diphosphates are 
typically formed by a head-to-tail condensation of isopentenyl diphosphate (IPP) with 
either dimethylallyl diphosphate (DMAPP) or the product of a previous such 
condensation, yielding linear terpenes that are extended by five carbons. Squalene, 
however, is made by the head-to-head condensation of two C15 farnesyl-diphosphates 
(FPP) to produce a symmetrical triterpene. The consequences of this are twofold. First, 
without the diphosphate, squalene is no longer activated for prenyl transfer to a 
hydrobenzoquinoid substrate (Figure 1.3-A, B). Second, cyclization of squalene gives a 
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characteristic arrangement of methyls that is not observed for adociasulfates or any other 
hydroquinone meroterpenoids (Figure 1.3-C). Occurrences of linear meroterpenoids in 
sponges have been noted, though not from sponges related to adociasulfate-producers.19 
Nonetheless, there is a precedent for prenyl transfer of linear triterpenes to quinones, as 
occurs in ubiquinone biosynthesis (Figure 1.3-B), while there is none for the equivalent 
transfer of squalene. 
 All sponge merotriterpenoids can potentially be derived from a common series of 
linear precursors (Figure 1.4). These universal precursors, the products of aromatic 
prenylation by hexaprenyl diphosphate, would then be cyclized via a proton-initiated 
(type II) carbocation-mediated cyclization cascade. Most adociasulfates are hydroxylated 
at one (e.g. AS-2) or both (e.g. AS-3) carbons at positions corresponding to alkenes in 
hexaprenyl diphosphate. This suggests that epoxidation of the linear substrate occurs 
prior to cyclization. The number and location of epoxides in the cyclization substrate 
provides a convenient way to group biosynthetically related sponge merotriterpenoids. 
Thus, group I merotriterpenoids are epoxidized at position 10,11, group II at both 
positions 6,7 and 10,11, and group III at position 6,7, while group IV compounds are not 
epoxidized (Figure 1.4). All proposed cyclization schemes described herein are based on 
(S,S) epoxide configurations, given the observed stereochemistry of the putative epoxide-
derived hydroxy-substituted carbons present in group I, II, and III adociasulfates.  
The simplest hypothetical cyclization schemes involve the group I 
meroterpenoids. Compounds in this group likely undergo two independent cyclization 
cascades and exhibit few rearrangements. The initial cyclization of AS-1, -2, -5, -6, -7, 
and halicloic acid A would be identical for each compound, with epoxide opening to 
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form a hydroxyl group at C11, establishing the four rings of the “adociasulfate core” 
(Figure 1.3-C) with ring D fused to the hydrobenzoquinone moiety (Figure 1.5-A).14-15, 
24 The resulting carbocation would then be quenched by proton abstraction, restoring 
aromaticity. A second proton-initiated cyclization of the remaining two olefins would 
produce a fifth ring and a carbocation at position C6. Here, AS-1, -5, and -7 could differ 
from AS-2, -6, and halicloic acid A in the manner of base abstraction. In the former 
group, deprotonation would occur at C5 to introduce a new double bond, leaving the fifth 
ring independent of the core, while in the latter group a sixth, seven-membered ring could 
be formed by attack of the C11 hydroxyl on the carbocation. Postcyclization proton 
abstraction would then occur at the cyclic ether oxygen. AS-10 likely undergoes the same 
initial cyclization as the other group I members, but would then involve a hydride shift 
after the second proton initiation event, placing the carbocation on C7 instead of C6 and 
resulting in a six-membered heterocycle instead of seven (Figure 1.5-B).17 The final 
structure of AS-2 would then be relatively flat with the terminal ring of AS-10 is twisted 
relative to the plane of the core. Halicloic acid B resembles AS-10, but its cyclization 
would involve an additional rearrangement: a methyl transfer following the hydride shift 
(Figure 1.5-C).24 This would place the carbocation on C2. Deprotonation at C3 would 
then yield a tri-substituted alkene. Halicloic acids A and B and AS-10 may use an 
alternative aromatic prenyl acceptor to hydrobenzoquinone, as a glycolic acid moiety 
substitutes for the hydroxyl at the 5’ position in these natural products. The final group I 
terpenes, toxicols A-C, may undergo a unique cyclization in which a rearrangement 
condenses the initial six-membered ring into a five-membered ring, resulting in an 
unstable secondary carbocation at C15.25 Cyclization would continue with subsequent 
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attack by C19 (Figure 1.5-D-i). Alternatively, C14 instead of C15 could directly attack 
C10 in the initial epoxide opening, which would be sterically hindered by the two axial 
methyls of C10 and C14 (Figure 1.5-D-ii). A second cyclization step and proton 
abstraction would result in the final product, with two independent ring systems. Finally, 
adociasulfates and related meroterpenoids would be sulfated at either, none, or both 
hydrobenzoquinone hydroxyls, while 5’ glycolic acids never appear to be modified 
further. 
 Adociasulfates and related meroterpenoids of group II are likely derived from a 
diepoxy precursor (Figure 1.6). Three of five members of this group exhibit a 5’ glycolic 
acid substitution akin to AS-10 and the halicloic acids.13, 16, 26 The primary proton-
initiated cyclization event of AS-9 may mirror that of AS-2 from group I, with the 
opening the 10,11-epoxide and establishment of the adociasulfate core. The second 
cyclization could involve the opening of the 6,7-epoxide by back-side attack of the C11 
hydroxyl at the more-substituted C6 position in a typical acid-catalyzed epoxide opening. 
This would result in the formation of a seven-membered ring and an inversion of C6 
stereochemistry. Assumption of a pro-chair conformation would position C6 into a pro-
(R) configuration relative to the C11 hydroxyl attack, resulting in an axial terminal olefin. 
For group I compounds, the lack of the 6,7-epoxide may allow for inclusion of the 2,3 
terminal alkene in the second cyclization event (Figure 3.4-A), whereas all group II 
compounds display a free terminal olefin. This may reflect the ease of protonating an 
epoxide over an alkene. 
 Group III merotriterpenoids are likely derived from a 6,7-epoxy precursor 
(Figure 1.7). This group is characterized by a lack of fusion to the aromatic ring and by 
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implied quenching with water. In the proposed cyclization of AS-3 and -4, initiation by 
protonation would result in a bicyclic drimane-like skeleton that undergoes 
rearrangement before deprotonation by an active-site base, yielding a highly stable tetra-
substituted double bond and unique configurations of methylated carbons (Figure 1.7-
A).14 The bond formed between C14 and C19 differs from those from groups I and II in 
that C19 would attack the pro-(S) face of the alkene as opposed to the pro-(R) face. 
Protonation of the 6,7-epoxide would initiate the second cyclization in AS-4 with the 
10,11 olefin, while hydrolysis of the epoxide would lead to AS-3. Both hydrolysis and 
cyclization would result in an inversion of C5 stereochemistry, similar to the 6,7-epoxide 
opening of AS-9. The first cyclization event of shaagrockol C would also produce a 
bicyclic system, though deprotonation would occur prior to any rearrangement, yielding a 
tetra-substituted alkene (Figure 1.7-B).27 The second cyclization would be similar to that 
of AS-4 but would occur from the opposite face of the 10,11 alkene, such that C11 has an 
(R) configuration instead of (S). A rearrangement would then follow immediately after 
ring formation and water would attack the C11 carbocation with inversion of 
stereochemistry. The net result of these dramatically different cyclization routes is that 
the newly formed ring of shaagrockol C would incorporate an axial hydroxyl in place of a 
proton, as in AS-4. Thus, shaagrockol C and AS-4 display the same relative configuration 
about C11, despite differing absolute configurations. Additionally, an attack from the 
pro-(R) face of the 10,11 alkene on the 6,7 protonated epoxide would place a large alkyl 
group in an unfavorable axial position. An attack from the pro-(S) face, which would 
place the same large group in the equatorial position, should be more favorable, but the 
occurrence of the less favorable pro-(R) route may allow for the addition of water over 
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deprotonation. Shaagrockol B, isolated together with shaagrockol C, is the oxidation 
product of C about the 22,23-alkene and is likely not enzymatic in origin.27 
 The remaining six known sponge merotriterpenoids of group IV may be derived 
from a substrate lacking epoxidation. The majority of these compounds undergo complex 
rearrangements, as evidenced by their atypical methyl positions. Like the group III 
compounds, none of the group IV members exhibit fused rings with the aromatic moiety, 
suggesting that aromatic ring fusion requires the presence of the 10,11-epoxide. Another 
common feature between groups III and IV is the absence of 5’ glycolic acid substitution. 
For AS-11 and -12, the proposed initial cyclization would again yield only a two-ring 
system, but would differ from groups I, II, and III in the attack of C23 on C18 from the 
pro-(S) face of the 22,23-alkene (Figure 1.8-A).18 In the previous merotriterpenoid 
groups, this attack likely occurs from the pro-(R) face. The bond between C14 and C19 
would be formed as in groups I and II. The second cyclization step of AS-11 and 
adociaquinol likely resembles that of AS-4 but, due to the absence of the 6,7-epoxide, 
would continue on to the terminal olefin. Deprotonation at the C9 methyl would 
introduce the exocyclic alkene. AS-12 likely undergoes hydride and methyl shifts prior to 
deprotonation, allowing the more stable trisubstituted alkene to form. The structure of 
AS-8 can be reached with a single proton-initiated cascade with extensive 
rearrangements, such that the end result appears structurally distinct from the 
adociasulfate core (Figure 1.8-B).15 In total, five hydride shifts and four methyl shifts 
would need to occur before an attack by water at the bridgehead carbon C7. Cyclization 
of the initial bicyclic ring system of toxiusol likely involves both of the atypical pro-(S)-
directed attacks of C23 on C18, as predicted for AS-11 and adociaquinol, and C19 on 
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C14, as predicted for the group III compounds (Figure 1.8-C).18, 25 Two hydride shifts 
and a methyl transfer would occur before deprotonation ends the first cyclization. The 
second proton initiated cascade of toxiusol would follow that of AS-12 but would include 
a second hydride transfer prior to deprotonation, placing the trisubstituted alkene on the 
opposite ring. The final sponge merotriterpenoid, akaterpin, likely follows a similar 
cyclization scheme as toxiusol but would involve an alkyl shift during the first 
cyclization that moves the remaining linear isoprene chain from C14 to the bridgehead 
carbon, C19 (Figure 1.8-D).28 
 After critical consideration of the origin of adociasulfates, it should be clear that 
all sponge merotriterpenoids of the hydrobenzoquinone family are related 
biosynthetically. In each adociasulfate discovery reported, mixtures of compounds from 
multiple groups were identified, suggesting a common synthetic route that is independent 
of the epoxidation state of the substrate.13-14, 16-18, 25 Of this class of compounds, all but 
one member has been isolated from sponges within the family Chalinidae. The exception 
is akaterpin, which was reportedly discovered from Callyspongia sp.28 Though 
Callyspongia is a member of the same order as Chalinidae (order Haplosclerida), 
Callyspongia is far enough removed in this case to be considered unrelated (Mary Kay 
Harper, personal communication). Thus, these compounds can be used as taxonomic 
identifiers, potentially due to a shared biosynthetic pathway. 
 
1.5 Considerations of the enzymatic origin of sponge merotriterpenoids 
Only a few key biosynthetic steps are required for all four groups of 
merotriterpenoids described above: aromatic prenylation, proton-initiated cyclization, and 
sulfation. Epoxidation also occurs for the majority of these compounds, with the 
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exception of those in group IV. The potential enzyme families responsible for these key 
steps of adociasulfate construction are discussed in this section. The source of the terpene 
and benzoquinone precursors is also considered, as these metabolites can be derived from 
multiple routes and the enzymes involved in their synthesis may be components of an 
adociasulfate biosynthetic gene cluster. In addition to the enzymatic origins of sponge 
merotriterpenoids, the identity of the producing organism is taken into account, as this 
will dramatically affect the genetic organization of the pathway (or lack thereof). 
 1.5.1 Origin of adociasulfate precursors. The majority of the adociasulfate 
structure is constructed of five carbon isoprene units. There are two known biosynthetic 
pathways for isoprene production: the mevalonate (MEV) pathway, which provides the 
precursors for steroid anabolism in eukaryotes but is also present in some bacteria, and 
the 1-deoxy-D-xylulose-5 phosphate (MEP/non-mevalonate) pathway unique to plants, 
bacteria, and some parasites (Figure 1.9). Both of these are considered primary metabolic 
pathways. It is possible that the adociasulfate pathway draws IPP directly from an 
endogenous metabolite pool and lacks any dedicated genes for IPP/DMAPP synthesis. 
However, the producing organism’s native isoprene source does not necessarily imply 
that pathway’s involvement in secondary metabolism. Bacteria normally lacking the 
MEV pathway, including the prolific natural product producing actinobacteria, are known 
to horizontally acquire MEV pathway genes and incorporate them into meroterpenoid 
biosynthetic clusters as a pathway-specific source of IPP/DMAPP.29-38 Some MEP 
pathway bacteria contain duplications of MEP genes in secondary metabolite clusters.39-40 
Gene duplication and divergence of endogenous biosynthetic proteins is one way in 
which enzymes with alternative substrate preferences or novel enzymatic functions have 
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evolved, especially in the context of secondary metabolism.41-44 The role of these 
seemingly redundant genes may be to enhance production of precursor metabolites, to 
impose distinct regulations on gene expression, or to provide a unique function. Both 
bacteria and eukaryotes are capable of this phenomenon. Thus, copies of genes with 
primary metabolic functions might be responsible for meroterpenoid production, as 
opposed to endogenous genes taking on dual primary and secondary metabolic roles. 
With several possible means of obtaining IPP/DMAPP for polyprenyl diphosphate 
synthesis and no guarantee that MEV- or MEP-pathway genes would be present in a 
hypothetical adociasulfate gene cluster, pathway identification should focus on the 
biosynthetic steps fundamental to adociasulfate production, and only consider the 
presence of isoprene pathway elements as a secondary indication of a terpene pathway. 
The adociasulfate prenyl donor, consisting of six isoprene units, is almost 
certainly a product of a trans isoprenyl diphosphate synthase (IPP synthase). IPP 
synthases are soluble, Mg2+-dependent prenyltransferases (PTases) mechanistically 
related to aromatic UbiA-like PTases discussed later on.45 These enzymes are responsible 
for producing prenyl diphosphates of different lengths for various biological functions, 
including polyprenyl diphosphates of 30-50 carbons in length used in the biosynthesis of 
ubiquinone, and the FPP used to make squalene in steroid biosynthesis. IPP synthases are 
sometimes components of meroterpenoid gene clusters.29-34, 37, 39 Their inclusion in 
secondary metabolite pathways may reflect a selection mechanism for a particular length 
polyprenyl substrate by establishing a distinct substrate pool for meroterpenoid 
biosynthesis separate from the endogenous isoprenyl diphosphate pool. In other 
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pathways, however, the lack of any IPP synthase gene suggests that native IPP synthases 
provide the prenyl substrate for secondary metabolism.  
While only two known pathways are responsible for isoprene production, the 
aromatic prenyl acceptor can be derived from a number of distinct pathways. All 
meroterpenoid pathways discussed in this review contain genes responsible for providing 
or modifying existing aromatic precursors. Understanding the function of such genes 
could aid in the recognition of a hydroquinone meroterpenoid pathway. Like prenyl 
diphosphates, quinones are also derived from primary metabolic pathways. According to 
the Kyoto Encyclopedia of Genes and Genomes (KEGG), hydroquinone and 4-
hydroxyphenylacetate (4HPA), a potential prehydroxylation precursor of the 5’-glycolic 
acid substituted adociasulfates, are both components of phenylalanine/tyrosine 
metabolism (Figure 1.10-A). In the model put forth by KEGG, 4HPA can be derived 
from 4-hydroxyphenylpyruvate (4HPP) and funnels into either the 4HPA degradation 
pathway of E. coli or the homogentisate pathway used by both prokaryotes and 
eukaryotes to metabolize phenylalanine and tyrosine, while hydroquinone can be 
obtained from homogentisate in a few enzymatic steps.46-47 However, poorly 
characterized, broad-substrate enzymes like aldehyde dehydrogenases and aldehyde 
oxidases are implicated in 4HPA and hydroquinone synthesis.48-49 The placement of these 
metabolites in the KEGG model is based on feeding studies with aromatic carbon sources 
in which aromatic substrates were shown to be metabolized via the 4HPA pathway, 
homogentisate pathway, or by a variation of the 3-oxoadipate pathway.46-47, 50 They are 
not endogenous metabolites and thus lack the potential to be used as prenyl acceptors as 
it may appear in the model. However, the enzymes of tyrosine metabolism may represent 
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functions required by the adociasulfate pathway. Oxidative decarboxylation, such as that 
catalyzed by 4HPP dioxygenase, an Fe2+-dependent internal ketoacid dioxygenase, could 
be used to generate hydroxy-4HPA from 4HPP.51 In a less direct route, 4HPA could 
potentially be obtained from 4HPP via 4HPA decarboxylase, which normally produces p-
cresol from 4HPA in Clostridium difficile and is a member of the glycyl radical enzymes 
(GRE) of the radical-SAM superfamily.52 Alternatively, decarboxylation of 4HPP to the 
aldehyde with subsequent oxidation to 4HPA by either an aldehyde dehydrogenase 
(ALDH), as indicated in the KEGG model, or an aldehyde oxidase (AOX), as shown by 
KEGG for the oxidation of gentisaldehyde to gentisate, could be possible. Both the 
NAD(P)+-dependent ALDHs and flavin-dependent molybdenum/tungsten AOXs are 
described as broad-substrate and are largely uncharacterized.48-49 Subsequent 
hydroxylation of the 4HPA acyl side-chain could be carried out by an a-ketoglutarate-
dependent Fe2+ enzyme or a cytochrome P450 (P450).53-54 Hydroquinone could be 
derived from gentisate by decarboxylation, potentially requiring a nonoxidative 
decarboxylase like 5-carboxyvanillate or g-resorcylate decarboxylase, both members of 
the ACMSD decarboxylase family.55-57 Oxidative decarboxylation of aromatic substrates 
can also be carried out by flavin monooxygenases.58 Though it is unclear what role 
tyrosine metabolism might play in providing the aromatic prenyl acceptor for 
meroterpenoid biosynthesis, the adociasulfate pathway may incorporate elements of these 
pathways in order to supply hydroquinone. 
Aromatic prenylation substrates are not solely derived from tyrosine or shikimate 
and could be generated de novo for adociasulfate biosynthesis. Hydroquinone prenyl 
acceptors of known meroterpenoid pathways are derived primarily from polyketides,30-31, 
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33, 37, 59-63 but can also be derived from tyrosine40, 64 and, quite remarkably, from the 
carbohydrate sedo-heptulose-7-phosphate (Figure 1.10-B).32 Another possibility is that 
the prenyl acceptor is extensively modified after the initial prenylation event, as is the 
case in ubiquinone synthesis (Figure 1.10-C). 4-hydroxybenzoate (4HB) and 
homogentisate, similar in structure to 4HPA and hydroquinone, are known prenyl 
acceptors in the ubiquinone and plastoquinone/tocopherol pathways, respectively.65-66 
Thus, there is a precedent for metabolites of tyrosine catabolism to act as prenyl donors. 
Prenyl-4HB/homogentisate could be decarboxylated and then hydroxylated to generate 
the precursor of adociasulfate cyclization. From the examples described here of the 
potential origin of the aromatic prenyl acceptor, it is unlikely that the adociasulfate 
pathway can derive its prenyl acceptor solely from primary metabolism. Thus, the 
pathway should include genes involved in the production of an aromatic substrate. The 
presence and interpretation of these genes can be used to facilitate meroterpenoid 
pathway identification.  
1.5.2 Prenylation. Prenyltransferase is the first true step in adociasulfate 
biosynthesis. A variety of aromatic prenyltransferases (PTases) are known to generate 
prenylated aromatic products resembling the linear adociasulfate precursors shown in 
Figure 1.4-A. The earliest to be characterized of these enzymes is 4HB-PTase, which is 
involved in the biosynthesis of ubiquinone.65, 67 4HB-PTases are present in all forms of 
life, as ubiquinone is an essential component of biological redox reactions like the 
electron transport chain. The mechanism of prenyl transfer by UbiA, the 4HB-PTase of 
E. coli, involves activation of the isoprene diphosphate to form a carbocation, initiating 
the electrophilic addition of 4HB.68-69 Both carbocation formation and electrophilic 
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addition require an active site constructed from two separate Asp-rich regions that are 
highly conserved amongst membrane-associated aromatic PTases.45, 68 Only recently 
have crystal structures become available for this family of PTases, though only structures 
of archaeal proteins that have not been biochemically characterized have been solved.69-70 
However, these and earlier modeling studies agree that coordination of the isoprenyl 
diphosphate with an active site Mg2+-ion induces formation of an isoprenyl carbocation 
that then condenses with 4HB, resulting in a Friedel-Crafts type alkylation.68-69 UbiA and 
related PTases are broadly substrate selective in vitro, especially with regard to the length 
of isoprenes that can be incorporated into their product.65, 71-72 Ubiquinone prenyl groups 
vary greatly in length within and between species.72 The protein structures of two 
archaeal UbiA homologs reveal a lateral opening into the hydrophobic interior of the 
lipid membrane that may provide access of long-chain isoprenes to the active site.69-70 
The prenyl chain presumably extends into the bilayer rather than be contained within the 
enzyme, allowing UbiA extreme substrate flexibility. UbiA also exhibits broad substrate 
specificity for prenyl acceptors, provided that these substrates are para-alcohol- or 
amino-substituted benzoates.73 In fact, membrane-associated aromatic PTases utilize a 
wide variety of aromatic prenyl acceptors in the biosynthesis of 
plastoquinones/tocopherols, menaquinone, and even secondary metabolites; a testament 
to their vast biosynthetic potential.74 It is likely, owing in particular to their 
accommodation of variable isoprene chain lengths, that membrane aromatic PTases are 
involved in sponge merotriterpenoid biosynthesis. The same rationale can be extended to 
meroterpenoids of other isoprene classes. 
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Prenylation of aromatic compounds is not unique to the UbiA family of PTases. 
The ABBA-family of aromatic PTases, so named for their alternating, antiparallel a-ß-ß-
a folds (dubbed the PT-fold or PT-barrel), are a more recently discovered family of 
soluble aromatic prenyltransferases involved in secondary metabolism of bacterial and 
fungal natural products.75-76 Since the characterization of the first ABBA PTase CloQ, 
responsible for condensation of DMAPP with 4HPP in the biosynthesis of the antibiotic 
clorobiocin, several additional members of the ABBA PTase family have been 
described.77 Some of these members utilize naphthalene-like prenyl acceptors: NphB and 
Fnq26 geranylate flaviolin in the biosynthesis of the antioxidant naphterin and 
furanonaphthoquinone I, respectively; HypSc adds DMAPP to 1,6-dihydroxynapthalene 
in vitro; SCO7190 was shown to prenylate hydroxynaphthalene, coumarin, and 1,3-
hydroxybenzene derivatives, including resveratrol; the fungal ABBA PTases PtfAt, PtfSs, 
and PtfBf condense 2,7-dihydroxynapthalene and DMAPP in vitro, though their biological 
substrates are unknown.30, 33, 78-79 Other ABBA PTases prenylate amino acids or peptides: 
the cyanobacterial AmbP1, WelP1, and FidP1 geranylate a tryptophan derivative, cis-
indolyl vinyl isonitrile, in the biosynthesis of ambiguine, welwitindolinone, and 
fischerindole, respectively; LynF O-prenylates Tyr residues of various cyanobactins, 
which encompass a broad class of cyanobacteria-derived macrocylic peptides.39, 80-81 Still 
other ABBA PTases use more diverse aromatic prenyl acceptors: PpzP adds DMAPP to 
5,10-dihydrophenazine-1-carboxylate in endophenazine A biosynthesis; DzmP is the only 
known ABBA PTase to use FPP to farnesylate its aromatic substrate, 
diabenzodiazepinone.29, 36 Fungal dimethylallyltryptophan synthases (DMATs) are 
structurally related to the CloQ-type and prenylate indole rings.82-83 DMATs are even 
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more limited than ABBA PTases in that they almost exclusively employ DMAPP. 
Additionally, the specificity of DMATs for aromatic prenyl acceptors other than indoles 
is either limited or has not been explored.84-85 In summary, ABBA PTases, though 
broadly substrate selective with regard to the aromatic prenyl acceptor, are restricted in 
the length of the prenyl donor to two or fewer isoprene units. While it is possible that 
ABBA prenyltransferases are responsible for merosesquiterpenoid biosynthesis, only one 
ABBA PTase is known to accept FPP as a prenyl donor.29 Despite the significant role of 
ABBA PTases in secondary metabolism, the comparison between PTase families better 
supports the idea that a membrane-associated PTase is involved in sponge meroterpenoid 
biosynthesis.  
1.5.3 Cyclization. Cyclization of linear terpenes is an electrophilic reaction 
catalyzed by terpene cyclases (also called terpene synthases). Triterpene cyclases of the 
class II squalene-hopane cyclase (SHC) and oxidosqualene-lanosterol cyclase (OSC) 
families are known for their broad substrate selectivity and their extreme product 
diversity in vitro.86-89 This latter property results from the potential for deprotonation 
after each cyclization step and at different positions, and from potential rearrangement. 
Terpene cyclases in general have proven to be highly engineerable; single amino acid 
changes can significantly alter product specificity.90-91 OSCs are eukaryotic in origin and 
are limited to formation of four-ring products from 2,3-oxidosqualene, while bacterial 
SHCs are responsible for production of the five-ring hopenes from squalene (Figure 1.3). 
SHCs accept a variety of terpene substrates in vitro, including 2,3-oxidosqualene, 
indicative of their greater substrate flexibility relative to OSCs.86, 92 Both SHCs and OSCs 
follow the same scheme with regard to product formation: substrate-binding in product-
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like conformation, initiation by protonation of the terminal isopropylidene alkene or 
oxirane, chaperoning cyclization by stabilization of carbocation intermediates, and 
termination by deprotonation or quenching with water. The initiation step imparts some 
control of substrate specificity for OSCs, as demonstrated by mutational studies of SHC 
wherein the ability of an SHC to cyclize squalene was abolished when the conserved 
SHC motif DDTAVV was replaced with the conserved OSC motif, DCTAEA.91 At the 
same time, improved in vitro cyclization of 2,3-oxidosqualene by the mutant SHC was 
observed. Product diversity is in part controlled by aromatic residues that line the active 
site of the enzyme and stabilize carbocation intermediates via p-cation interactions, and 
also by residues positioned at the end of the cyclization cascade that are responsible for 
the deprotonation. Terpene cyclization is a highly stereospecific reaction, resulting in 
characteristic configurations about the chiral bridgehead and methyl-substituted carbons. 
The shape of the active site cavity likely plays a large role in determining the 
arrangement of the rings in the final product, and whether deprotonation terminates 
cyclization or the addition of water. Many adociasulfates display sterol-like 
stereochemistry within rings A-C, indicative of the “prechair” conformation assumed by 
group I adociasulfates prior to cyclization that is characteristic of both sterol and hopene 
cyclizations.86 The position of the methyl at C21 in the adociasulfate core is shifted by 
one carbon relative to hopene and lanosterol due to the use of a head-to-tail versus head-
to-head terpene precursor (Figure 1.3). Some adociasulfates exhibit early termination, 
resulting in only a two-ring system. This phenomenon has also been observed for 
SHC/OSCs in vitro.86, 89 While flexibility of SHCs and OSCs has been shown in vitro, 
this does not necessarily translate to the same flexibility in vivo. Still, a class II terpene 
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cyclase is a likely candidate for an adociasulfate synthase given the nature of SHC and 
OSC substrates.  
SHCs and OSCs have been shown to accept linear hydroquinone meroterpenoids 
as substrates in vitro.88, 93-95 In these examples, SHCs are able to cyclize the prenyl side 
chain of the linear meroterpenoid substrate, but their products lack fusion of the aromatic 
moiety with the terpene ring system.93, 95 An exception is SHC from Zymomonas mobilis, 
(ZmoSHC1) which fused a phenol ring with C10 and C15 isoprenes, but not C20.88 The 
OSC lupeol synthase (LUP1) from Arabidopsis thaliana is capable of forming in vitro 
petromindole, a fungal indole meroditerpenoid, from linear 3-(w-
oxidogeranylgeranyl)indole, successfully fusing the aromatic indole ring to the prenyl 
side chain.94 This may reflect enzyme-specific preferences of OSC for the epoxide 
substrate, or a mechanistic difference in how LUP1 and ZmoSHC1 deal with termination 
of cyclization. The linear adociasulfate substrate is likely epoxidized at the 6,7 or 10,11 
positions rather than at the 2,3 position. Some OSCs are able to cyclize 2,3-22,23-
dioxidosqualene, but cyclization of internal epoxides is not known.96-97 Proton initiation 
at the internal epoxides of adociasulfate precursors is potentially responsible for allowing 
some adociasulfates to escape cyclization of the 2,3 alkene. Additionally, adociasulfate 
cyclization events sometimes involve heterocycle formation via hydroxyls produced by 
putative epoxide ring openings. SHCs are capable of heterocycle formation in this way.98 
Despite the presence of epoxides, some adociasulfate cyclizations do not involve epoxide 
openings, even amongst those with epoxide substrates like AS-3/4 (Figure 1.7-A). Thus, 
it is more likely that an SHC adapted to initiation at epoxides is responsible for 
adociasulfate cyclization. Sponge meroterpenoids of smaller prenyl lengths do not exhibit 
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epoxidation of substrates and would not likely be cyclized by OSCs. Alternatively, class 
II diterpene cyclases exist that could act on C20 and possibly C15 substrates by proton-
initiated cyclization.99-101 In addition to the classical terpene cyclases, other 
meroterpenoid pathways may contain terpene cyclases specialized for linear aromatic 
meroterpenoid precursors.32, 102 These have the potential to be pathway-specific and 
mechanistically novel, but also difficult to recognize as terpene cyclases. For example, 
P450s have been show to catalyze terpene cyclizations.103-104 
Epoxidation of squalene in eukaryotes is carried out by squalene monooxygenase 
(SM), a membrane-bound flavin-dependent protein that requires molecular oxygen and 
reduced NADPH, as well as a P450 reductase partner.105 The requirement for a P450 
reductase is unique amongst flavin-dependent monooxygenases, as there is no structural 
relationship between SM and P450s, but several groups of flavin monooxygenases are 
known to require other flavin reductase partners.58 There is evidence that a second, non-
P450 type flavin reductase may be also be able to supply reduced NADPH to SM.106 
There is a precedent for SM in secondary metabolism, as the diterpene phenalinolactone, 
produced by a Streptomyces strain, includes an SM homolog in its biosynthetic gene 
cluster.107 This SM homolog is believed to introduce an epoxide at the terminal olefin of 
the C20 geranylgeranyl diphosphate substrate. However, SM produces a single isomer of 
oxidosqualene, introducing an oxirane ring at the 2,3 position in the (S) configuration. It 
is possible that a related enzyme is responsible for the formation of the internal 6,7- and 
10,11 epoxides of the adociasulfate precursor, but due to the rigid specificity of SM for 
terminal olefins it is likely that an unrelated monooxygenase is involved. P450 
monooxygenases are involved in oxidative tailoring reactions in numerous natural 
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product pathways and are capable of performing a wide variety of chemical modifications 
on diverse substrates, including epoxidation. P450s are also important in the metabolism 
of xenobiotics and drugs in animals.108 All P450s obtain reduced flavin via a P450 
reductase partner, similar to SM.109 Owing to their incredible diversity in both function 
and substrate specificity, this class of enzymes is a likely candidate for epoxidation in the 
adociasulfate pathway.  
1.5.4 Sulfation. The final step in the synthesis of adociasulfates is sulfation of the 
hydroquinone moiety. In eukaryotes, sulfation is carried out by sulfotransferases (SULTs) 
that utilize 3’-phosphoadenosine 5’-phosphosulfate (PAPS) as a sulfonate (SO3-) donor. 
Sulfation substrates include glycosaminoglycans, proteins, lipids, hormones, and various 
drugs.110 The role of sulfation varies, but is involved in cell signaling, molecular 
recognition, and detoxification.111 Though SULTs are less prevalent in bacteria, a 
diversity of sulfated molecules exists, for many of which sulfation has a profound impact 
on biological function. Some of these functions involve interactions with eukaryotes. 
Commensal gut bacteria have been implicated in the sulfation of antibiotics in 
mammals.112 Sulfated glycolipids are involved in establishing stable infections of 
symbionts within their eukaryotic hosts. and also play a role in bacterial pathogenesis.113-
114 Sulfation has been incorporated into secondary metabolism as well, where SULT 
domains have been identified within polyketide synthases to generate sulfated products, 
or, in one case, sulfation activates a substrate for decarboxylation.115 Sulfated 
glycopeptide antibiotics exhibit reduced activation of resistance in antibiotic-resistant 
bacteria relative to their nonsulfated counterparts, potentially by preventing dimerization 
of antibiotics.116 The role of sulfation in adociasulfate activity can only be guessed, as the 
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native biological function of adociasulfates is not known. However, with regard to 
kinesin, the sulfates only prevent membrane penetration and do not affect inhibition.6, 13 
Sulfation could be a mechanism for elimination to avoid toxicity associated with kinesin 
inhibition, or it could enhance secretion to facilitate exposure to predators. Not all sponge 
merotriterpenoids are sulfated, however, but these compounds have not been tested for 
kinesin inhibition.24, 26 It has been suggested that an AS-14 analog containing an 
esterified glycolic acid moiety and lacking sulfation might be membrane permeable and 
still inhibit kinesin, making it a good anticancer lead.13 Haliclotriol A and haliclotriol 
triacetate closely resemble this hypothetical analog and should be screened for kinesin 
inhibition.26 Still, sulfation is not essential for adociasulfate biosynthesis, and the genes 
involved need not reside in the same gene cluster or even the same genome as the rest of 
the pathway. While either host or symbiont may produce adociasulfates, the other 
symbiotic partner may be responsible for their sulfation. 
In addition to SULTs, a distinct clade of sulfotransferases, the arylsulfate 
sulfotransferases (ASSTs), exists that is PAPS-independent, using instead aryl sulfates, 
often phenolic, as sulfonate donors.117 This small group of sulfotransferases is restricted 
to bacteria, including commensal and pathogenic bacteria.112, 118 Native aryl sulfonate 
donors remain unknown for each of the few identified ASSTs, except for Cpz4 of the 
biosynthetic pathway for the liponucleoside antibiotic, caprazamycin.119 Encoded within 
the cpz gene cluster is the ASST cpz4 in addition to a SULT and a type III PKS (cpz8 and 
cpz6, respectively). The Cpz6 product acts as the sulfonate donor after it itself is sulfated 
by Cpz8. Additionally, Cpz4 transfers its sulfonate group to a non-aryl substrate, 
suggesting there is potential for broader substrate diversity amongst ASSTs. Thus, 
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SULTs are not the only sulfotransferase capable of adociasulfate sulfation; bacterial 
ASSTs may be responsible. 
 
1.6 Concluding remarks 
Sponge meroterpenoids exhibit broad biological activity, but some display unique 
mechanisms of action. For these compounds, a sustainable and economic source is highly 
desirable. Chemical synthesis of adociasulfates has proved difficult and isolation from 
nature is not environmentally feasible.120-122 A biosynthetic strategy would require 
knowledge of the native pathway. This review is aimed at dissecting the adociasulfate 
structure, highlighting key structural features that provide mechanistic clues toward the 
identification of the enzymes involved. The pattern of adociasulfate cyclization suggests 
of a squalene-hopene cyclase (Figure 1.11). The positions of the epoxides in the linear 
adociasulfate precursor suggest that squalene monooxygenase is unlikely to be involved; 
instead, a P450 may be responsible. The use of a head-to-tail linear triterpene precursor 
instead of squalene supports the idea that a polyprenyl synthase supplies the precursor to 
cyclization. These observations, which encompass the more distinct features of the 
adociasulfate structure, imply a bacterial origin. No biosynthetic pathways for sponge 
meroterpenoids have ever been identified, so there is no reference to base this conclusion 
on. In only one case has a producing organism been claimed to have been identified – for 
the production of avarol, a merosesquiterpenoid, by the sponge Dysidea avara. In these 
studies, avarol was traced to a specific sponge cell type and production was later 
observed from an axenic primary sponge culture.123-124 No publications have followed 
these studies in nearly 17 years. In an effort to identify the biosynthetic genes involved in 
ilimaquinone production from Hippospongia sp., I could not identify any biosynthetic 
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gene clusters by metagenome mining consistent with the biosynthetic features proposed 
for adociasulfate biosynthesis. This could reflect a lack of clustering and/or the absence 
of bacterial production, or a biosynthetic pathway entirely unrelated to that proposed for 
the adociasulfates. Thus, the possibility exists that adociasulfates and related 
meroterpenoids are sponge-derived, though merosesquiterpenoid biosynthesis may differ 
substantially with that of merotriterpenoids. The most consistent sponge-based 
biosynthetic origin would involve an off-shoot of ubiquinone synthesis, with cyclization 
catalyzed by an oxidosqualene cyclase. 
Though the structure of adociasulfates favors symbiont-derived production over 
sponge-derived, no clear verdict can be obtained without experimental investigation. 
Clues as to what types of enzymes are responsible have been described here. Targeted 
searches of genes with these functions could help to identify the adociasulfate pathway. 
Metagenomic approaches may complicate data interpretation in that several to hundreds 
of gene homologs may be identified within a single metagenome, especially for those 
genes related to primary pathways, such as ubiA. A comparative metagenomics approach 
may resolve these issues, in which the metagenomes of nonproducing Chalinidae 
sponges are sequenced alongside adociasulfate-producing specimens to enable 
comparative analysis. While metagenome sequencing was attempted for Cladocroce 
aculeata, from which AS-8, -13, and -14 were characterized by Chris Ireland’s lab, poor 
quality DNA was isolated from frozen samples.13 Care must be taken to collect and 
prepare samples for analysis of by chemical and DNA sequencing approaches. Following 
the guidelines for pathway identification laid out in this review may result in successful 
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recognition of a meroterpenoid pathway, opening the door for biosynthetic approaches to 


















Figure 1.1. Structures of microtubule-competitive kinesin inhibitors. The 
polyoxometalate NSC 622124 [K6Mo18O62P2]6– assumes a Dawson structure. Dawson 
structure image reprinted from Chemistry & Biology, 15, R. Prudent et al., “Identification 
of Polyoxometalates as Nanomolar Noncompetitive Inhibitors of Protein Kinase CK2”, 






















Figure 1.2. Chemical structures of related sponge merotriterpenoids. The adociasulfates 
and related compounds are derived from sponges of the family Chalinidae, with the 







Figure 1.3. A comparison of the biosynthesis of squalene (left column) and polyprenyl 
diphosphate (right column). A) The condensation of two FPP molecules in head-to-head 
orientation yields squalene, while iterative head-to-tail prenylation results in hexaprenyl 
diphosphate. 2,3-oxidosqualene is the precursor for cyclization in the synthesis of 
hopenes and sterols. B) Polyprenyl diphosphates are substrates for aromatic prenylation 
in the synthesis of ubiquinone. C) The adociasulfate core present in many sponge 

















Figure 1.4. The four putative adociasulfate biosynthetic classes. A) Sponge 
merotriterpenoids can be divided into four groups by the number and position of 
















Figure 1.5. Putative cyclization routes of group I sponge merotriterpenoids. Group I 
compounds are derived from 10,11-epoxyhexaprenyl diphosphate. A) Cyclization of the 
adociasulfate core of AS-1, -2, -5, -6, -7, and halicloic acid A occurs with an “all chair” 
arrangement similar to hopene/sterol cyclization. A second cyclization involving the 
remaining terminal olefins event involves either direction deprotonation (i) or attack by 
the C11 hydroxyl (ii). B) The initial cyclization event of AS-10 is identical to those in 
Figure 1.5-A. The second cyclization involves a proton transfer prior to attack by the C11 
hydroxyl. C) The initial cyclization event of halicloic acid B is identical to those in 
Figure 1.5-A. The second cyclization follows that of AS-10 but the proton shift is 
followed by a methyl transfer. Deprotonation occurs instead of hydroxyl attack. D) The 
initial cyclization event of the toxicols may follow that in Figure 1.5-A but would include 
a rearrangement that collapses the six-membered A-ring into a five-membered ring (i). 
Alternatively, the initial cyclization may yield the five-membered ring directly (ii). The 








































































































Figure 1.6. Putative cyclization routes of group II sponge merotriterpenoids. Group II 
compounds are derived from 6,7-10,11-diepoxyhexaprenyl diphosphate. The initial 
cyclization event is identical to that shown in Figure 1.5-A, resulting in the adociasulfate 
core ring system. The second cyclization involves epoxide opening of the 6,7-oxirane 










Figure 1.7. Putative cyclization routes of group III sponge merotriterpenoids. Group III 
compounds are derived from 6,7-epoxyhexaprenyl diphosphate. A) The initial cyclization 
event of AS-3 and -4 yields a drimane-like two-ring system with a free hydroquinone 
moiety. The second cyclization involves epoxide opening of the 6,7-oxirane ring either 
by attack the 10,11 alkene for AS-4, producing a second bicyclic ring system (i), or attack 
by water for AS-3, yielding a diol (ii). B) The initial cyclization of shaagrockol C is 
similar to that of AS-3 and -4 but involves direct deprotonation without rearrangement. 
The second cyclization involves epoxide opening of the 6,7-oxirane ring by attack the 
10,11 alkene followed by attack by water, then a third cyclization between the terminal 



























Figure 1.8. Putative cyclization routes of group IV sponge merotriterpenoids. Group IV 
compounds are derived from hexaprenyl diphosphate. A) The initial cyclization of AS-
11, -12, and adociaquinol is similar to that of AS-3 and -4 but the attack of C19 on C14 
occurs on a different face of the 14,15 alkene. The second cyclization results in a second 
bicyclic ring system, with either direct deprotonation to produce AS-11 and adociaquinol, 
or rearrangement followed by deprotonation to generate a more stable tertiary alkene in 
AS-12. B) The cyclization of AS-8 involves all six alkenes, but not hydroquinone, 
resulting in a five-membered ring system. Extensive rearrangement ensues, totaling five 
proton shifts and four methyl transfers. A final attack by water quenches the carbocation. 
C) The initial cyclization of toxiusol is similar to that of AS-3 and -4 in Figure 1.7-A. 
The second cyclization event follows that of AS-12 but includes an additional proton 
transfer across the bicyclic ring system. D) The initial cyclization of toxiusol is similar to 
that of AS-3 and -4 in Figure 1.7-A. The second cyclization event follows that of AS-12 













































































Figure 1.9. Isoprene biosynthesis by the mevalonate (MEV) and non-mevalonate (MEP) 
pathways. The MEV and MEP pathways are named based on their intermediate 
metabolites mevalonate and 2-C-methyl-D-erythritol-4-phosphate, respectively. Genes 








Figure 1.10. Potential biosynthetic origins of the aromatic prenyl acceptor. A) Tyrosine 
metabolism pathways, as mapped by KEGG. Dashed arrows indicate improbable 
enzymatic transformations. B) Examples of unique metabolic origins of the aromatic 
moiety in quinone meroterpenoid natural product pathways.32, 59 C) The aromatic prenyl 
























Figure 1.11. A biogenetic hypothesis for the adociasulfates. A) A hypothetical 
adociasulfate gene cluster was constructed based on the most likely biosynthetic origin, 
as addressed in this review. In this scenario, the pathway is assumed to be part of a 
bacterial genome. Black genes represent those directly involved in biosynthesis, white 
genes are those indirectly involved in biosynthesis, and those bordered with a dashed line 
have the potential to be entirely absent from the cluster. B) A biosynthetic scheme 
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Two merotriterpenoid hydroquinone sulfates designated adociasul-
fate-13 (1) and adociasulfate-14 (2) were puriﬁed from Cladocroce
aculeata (Chalinidae) along with adociasulfate-8. All three com-
pounds were found to inhibit microtubule-stimulated ATPase activ-
ity of kinesin at 15 μM by blocking both the binding of microtubules
and the processive motion of kinesin along microtubules. These
ﬁndings directly show that substitution of the 5′-sulfate in 1 for a
glycolic acid moiety in 2 maintains kinesin inhibition. Nomarski im-
aging and bead diffusion assays in the presence of adociasulfates
showed no signs of either free-ﬂoating or bead-bound adociasul-
fate aggregates. Single-molecule biophysical experiments also sug-
gest that inhibition of kinesin activity does not involve adociasulfate
aggregation. Furthermore, both mitotic and nonmitotic kinesins are
inhibited by adociasulfates to a signiﬁcantly different extent. We
also report evidence that microtubule binding of nonkinesin micro-
tubule binding domains may be affected by adociasulfates.
single-molecule biophysics | natural products | mechanism of action |
microtubule-based motors | terpenes
Kinesin motor proteins are implicated in several vital eukaryoticcellular processes, including vesicle transport (1) and mitosis
(2). They are composed of three distinct domains: a motor domain
that both hydrolyzes ATP and steps along microtubules (MTs),
a linker domain involved in dimerization, and a cargo binding tail
domain. Inhibitors of these enzymes can provide key information
concerning the mechanism of coupling ATP hydrolysis to the char-
acteristic stepping motion of kinesins. In addition, kinesins con-
trol cellular functions that are often implicated in disease. Hence,
kinesin inhibitors are highly sought. Of the known kinesin inhib-
itors, monastrol (3), terpendole E (4), HR22C16 (5), CK0106023
(6), S-trityl-L-cysteine (7), and the dihydropyrazoles (8), including
ispinesib (9), inhibit ATPase activity of Eg5 allosterically, allowing
ATP binding but preventing ADP release. Rose bengal lactone
(RBL) inhibits MT-stimulated ATPase activity of kinesin (10).
Thiazole inhibitors compete with ATP directly to inhibit Eg5 (11),
whereas biaryl compounds GSK-1 and GSK-2 block interactions
with nucleotides through an allosteric binding site (12). Adocia-
sulfates are unique in that they are the only kinesin inhibitors with
mechanisms of action that involve competition for binding to MTs
(13, 14). Thus, they have the potential to be used as probes for
kinesin functions unaffected by other inhibitors or drugs that
target these functions speciﬁcally.
Adociasulfates are a subfamily of sulfated triterpenoid hydro-
quinone compounds derived from marine sponges of the family
Chalinidae. They have received attention for their inhibitory ef-
fect on kinesin family motors and H+-ATPase proton pump
enzymes, where their activity has been linked to the presence of at
least one sulfate group (15). Much of what is known about ado-
ciasulfate activity comes from studies of adociasulfate-2 [AS-2
(4)]. The compound is known to bind to kinesin and interfere
with MT binding with minor effects on nucleotide interactions
(13, 14). The idea that adociasulfates are 1:1 kinesin inhibitors
has been questioned in a recent study suggesting that 4 forms
extended aggregates that mimic the negatively charged microtu-
bule surface and thereby, inhibit kinesin activity (16). The mode
of binding to kinesin is a critical question for future drug de-
velopment. Speciﬁc inhibition would make these compounds
more suitable to target a small class of enzymes, whereas aggre-
gation would make practical in vivo applications problematic. At
the same time, aggregations of small molecules could be poten-
tially interesting in nanobiological engineering, where artiﬁcial
microtubule tracks are highly desirable.
We report the discovery of two previously undescribed adocia-
sulfates, which we designate adociasulfate-13 (1) and adociasulfate-
14 (2), isolated from the marine sponge Cladocroce aculeata
Pulitzer-Finali, 1982 (Fig. 1). Adociasulfate-8 (3) was also isolated
from the same organism. We have used single-molecule bio-
physical measurements to assess the activity of these compounds
against kinesin-1 and -5 family motor proteins. We also assessed
whether the inhibitory activity of these compounds is connected to
the formation of extended adociasulfate aggregates. Our results
suggest that compounds 1, 2, and 3 inhibit both binding of kinesin
to MTs and processive motion. The replacement of the 5′-sulfate
with a glycolic acid moiety has little effect on kinesin inhibition,
indicating that alternative functional groups may be capable of
maintaining activity. We note that this observation signiﬁcantly
Signiﬁcance
Kinesin motor proteins are central to cellular processes and
considered good drug targets, but very few reported kinesin
inhibitors exhibit potential as drugs. Adociasulfates uniquely
inhibit kinesins by competing with microtubules for binding. A
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limiting potential therapeutic applications. In this study, we
show that kinesin inhibition is likely a 1:1 interaction and does
not involve aggregates. We suggest a means by which cell
permeability may be improved and show that adociasulfates
inhibit kinesin-1 and -5 families of motors to a signiﬁcantly
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enhances the value of adociasulfates as a target for future drug
development. We corroborate and extend the previously pro-
posed theory that adociasulfates act as MT mimics, but we ﬁnd
no evidence that large aggregates of individual adociasulfate
molecules could be responsible for the observed activity. We
also provide evidence that adociasulfates inhibit kinesins at the
single-molecule level.
Results
Structure Elucidation of AS-13 and AS-14. High-resolution mass
measurement of the [M-H]– ion of AS-13 (1) resulted in a pre-
dicted chemical formula of C36H54O10S2 with 10 double-bond
equivalents. A loss of 80 Da in the negative ion mode suggested
the presence of a sulfate group (Fig. S1A). The carbon skeleton
of AS-13 (1) is identical to AS-9 (5), which was determined from
1H, 13C, and heteronuclear multiple bond correlation (HMBC)
NMR data (Figs. S2 and S3D, summarized in Table S1) (17).
Rotating-frame nuclear Overhauser effect correlation spectros-
copy (ROESY) correlations conﬁrmed that the conﬁgurations of
all methyls, ring junction methines, and hydroxymethines match
those conﬁgurations previously reported (Fig. S3F and Table S1).
A quaternary carbon presumed to be C9 was not observed by
13C or HMBC NMR experiments. A 13C spectrum recorded in
DMSO-d6 revealed all 36 carbons (Fig. S2C). Taken together,
these data are consistent with 1 being the disulfated version of 5.
Adociasulfate-14 (2) has a molecular formula of C38H56O9S
with 11 double-bond equivalents as determined from the high-
resolution mass of the [M-H]– ion, indicating the addition of two
carbons relative to 1 and 3 (Fig. S1B). The 1H NMR spectrum
recorded in DMSO-d6 identiﬁed an additional oxymethine rela-
tive to 1 that was signiﬁcantly more deshielded than the other two
(δH = 4.78, 3.58, and 3.44 ppm for 2; δH = 3.76 and 3.51 for 1; Fig.
S4A). A carbonyl carbon (δC = 175.7 ppm) and an additional
heteroatom-bound carbon were also identiﬁed by 13C NMR (Fig.
S3B). The carbon skeleton and stereocenter conﬁgurations were
shown to be similar to 1 by HMBC and ROESY correlations
(Fig. S5 D and F, summarized in Table S2). The conﬁguration
of H-6 could not be conﬁdently assigned because of the pres-
ence of ROESY correlations from methyl H3-26 to both H-6
and 6-OH. The splitting of H-6 is broad in DMSO-d6 (Fig.
S4A), but it is a triplet with J = 6.9 Hz in MeOH-d4 (Fig. S4B),
suggesting that multiple conformations may exist in which H-6
is either pseudoaxial or -equatorial. The position of the glycolic
acid group on the aromatic ring relative to the sulfate group
was conﬁrmed from ROESY correlations between H-7′ and both
H-20ax and H-20eq. The conﬁguration of the stereocenter at po-
sition 7′ was not determined. Two methylene protons at positions
15 and 19 were not observed throughout all NMR experiments,
likely because of overlapping chemical shifts. Collectively, these
data suggest that 2 is identical to 1 with one sulfate replaced by
a glycolic acid moiety. Adociasulfate-10 (6) is the only other ado-
ciasulfate reported with such a feature (15).
Adociasulfate-8 (3) was identiﬁed from the high-resolution
mass of the [M-H]– ion (m/z = 695.3300; ∆ = −1.0 ppm) pre-
dicting a chemical formula of C36H55S2O9 (Fig. S1C) and com-
parison of NMR data with reported chemical shift values and
HMBC/ROESY correlations in DMSO-d6 (18). A 1H NMR
spectrum is provided in the supplementary material to indicate
sample purity (Fig. S6).
Adociasulfates Are Potent Inhibitors of Kinesin. The adociasulfates
reported here share signiﬁcant structural similarity with AS-2
(4), AS-10 (6), and AS-6 (7), which are known to be strong
inhibitors of MT-stimulated activity of kinesin ATPases. We
used a bead motility assay to test whether AS-13 (1), AS-14 (2),
and AS-8 (3) also showed this inhibitory activity. Beads pre-
incubated with increasing amounts of kinesin heavy chain iso-
form 5A (KIF5A) motors showed increased binding to MTs (Fig.
(1) R = OSO3 , R' = SO3
(2) R = CH(OH)COO , R' = SO3



























Fig. 1. Chemical structures of adociasulfates.




































2). The addition of 15 μM adociasulfates dramatically reduced
bead–MT binding. Beads that bound nearly universally to MTs in
the absence of adociasulfates showed negligible binding in the
presence of 1, 2, or 3. MT binding could be rescued by incubating
the beads with higher concentrations of kinesin. Compound 2
showed a pattern of kinesin–MT binding inhibition similar to the
observations for 3, whereas 1 showed the strongest inhibitory ac-
tivity (Fig. 2 and Fig. S7). The half maximal inhibitory concen-
tration of 4, 6, and 7 varies somewhat with tubulin concentration
but has been reported to be within the 2–6 μM range, with near
complete inhibition of ATPase activity at 15 μM (14, 15, 19).
Therefore, 1, 2, and 3 seem to have comparable inhibition with
4, 6, and 7. No signiﬁcant effect on kinesin–MT binding was
seen in the presence of 15 μM cholesterol (Fig. 2), which shares
many structural features with 1 and 2 but lacks the sulfated
aromatic ring.
The three adociasulfates examined were also observed to se-
verely inhibit processive motion of kinesin on MTs. In assays
where 1, 2, or 3 was present and the kinesin–MT bead binding
fraction was below 30% (corresponding to a regime where only
a single motor is likely to be active), kinesin stepping along MTs
was below our detection: less than 40–50 nm (ﬁve to six steps) if
at all present. Note that bound beads underwent constrained
Brownian motion that made it difﬁcult to observe extremely short
and fast processive motion events. Single-kinesin processive mo-
tion was readily observable in the absence of adociasulfates.
Large Aggregates of Adociasulfates Are Not Required for Kinesin
Inhibition. It is presently unclear whether adociasulfates are 1:1
inhibitors of kinesin or whether the binding to MTs is inhibited
by extended adociasulfate aggregates. Large aggregates of 4
rather than individual molecules have been previously reported
to be responsible for kinesin inhibition (16). We attempted to
detect such aggregates in our assays and elucidate the mode by
which 1, 2, and 3 inhibit kinesin. Aggregates extending 200 nm
across, which were described by Reddie et al. (16), are well
within the resolution of our imaging, which allows us to clearly
resolve individual microtubules (∼25-nm diameter). We ob-
served no evidence of adociasulfates forming extended or glob-
ular structures in our assays (Fig. S8A) and found no evidence of
adociasulfate aggregation in turbidity assays (Fig. S8C). Addi-
tionally, bead motion displayed comparable Brownian character
between adociasulfate and control assays, suggesting that no
extended objects were attached to the bead-bound motors (Fig.
2B). Finally, we observed no elevated bead-to-bead binding in
adociasulfate assays. Such cross-linking would be expected if
beads bound by multiple motors were interacting with extended
structures in solution. Reddie et al. (16) reported that activity
of 4 changed with longer adociasulfate incubation times. Our
results were not altered when preincubation times with adocia-
sulfates were extended to 10 min.
Adociasulfates Show Broad Microtubule Mimic Activity.We assessed
whether adociasulfates inhibit MT binding for nonkinesin MT
binding domains by examining the MT binding of two mitotic
kinesins: Eg5 and BimC (Fig. 3). Both proteins belong to the
kinesin-5 family of motor proteins. BimC possesses a unique
N-terminal domain rich in positive residues and vaguely ho-
mologous to the MT binding region of microtubule-associated
protein 2 (MAP2) (20). This domain is known to dramatically
increase BimC binding to MTs relative to motor proteins lacking
such a domain (20). Note that MT binding domains of kinesins
have been directly implicated as the sites of adociasulfate bind-
ing and that Eg5 and BimC possess highly homologous MT
binding regions within the motor domains (Fig. 3A) (13, 14).
Overall, inhibition is signiﬁcantly less pronounced for mitotic
kinesins versus kinesin-1 motors. This observation is consistent
with a previous report that IC50 values of AS-2 (4) for kinesin-1
and centromere protein E (CENP-E) motors differ by as much as
a factor of ﬁve (14). Therefore, although adociasulfates inhibit
kinesins across many motor families (13, 14), they may be useful
at low micromolar concentrations as speciﬁc inhibitors of some
nonmitotic kinesins. Additional work is needed to investigate
how different classes of kinesins are affected by adociasulfates.
Discussion
The increasing diversity of known adociasulfate inhibitors of
kinesin allows us to speculate about key structural features re-
quired for binding to kinesin. Knowledge of the structure activity
relationship (SAR) of adociasulfates is limited by incomplete
information on the kinesin activity of all known family members.
Fig. 2. The effect of AS-8, -13, and -14 on kinesin–MT binding. (A) Beads pre-
incubated with different amounts of kinesin-I motors were tested for MT
binding activity. All binding fraction data sets were well ﬁt by single-molecule
Poisson distribution P(n) = 1 − exp(−n/b) (solid lines; n, relative motor concen-
tration; b, effective binding afﬁnity). Estimated binding afﬁnities were 3.5e-6 ±
0.3e-6, 4.3e-6 ± 0.3e-6, 5.1e-5 ± 0.9e-5, 5.5e-5 ± 0.7e-5, and 1.1e-4 ± 0.2e-4 for
KIF5A alone, KIF5A + cholesterol, KIF5A + AS-8 (3), KIF5A + AS-13 (1), and
KIF5A + AS-14 (2), respectively. Error bars: 95% conﬁdence interval for bi-
nomial distribution. (B) Mean squared displacement curves for ﬂoating KIF5A
beads preincubated with 1, without 1, and with short MTs in the absence of
ATP (n = 9, 10, and 17, respectively). Computed mean squared displacement
yielded excellent linear ﬁts (solid lines; all adjusted R square > 0.9995; error
bars = SEM) indicative of pure diffusion. The MT assay mean squared dis-
placement curve indicates lower bead diffusion than for the other two assays.








It is clear, however, that the 2′ sulfate does not signiﬁcantly con-
tribute to activity (19). In addition, substitution of the 5′ sulfate for
a glycolic acid moiety in 6 does not signiﬁcantly alter kinesin in-
hibition compared with 4 (15). The similarity between the activities
of 1 and 2 is in agreement with this observation and is more con-
vincing because these two compounds are otherwise identical. This
result suggests that an α-hydroxyacid is a sufﬁcient bioisostere for
the 5′ sulfate, perhaps because of the negative charge shared
by the two functional groups, raising the possibility that functional
groups other than sulfates may confer bioactivity. If so, these
ﬁndings may aid in the discovery of more cell-permeable kinesin
inhibitors. For example, the methyl esters of glycolic acid-
substituted adociasulfates could potentially act as prodrugs, pen-
etrating the cell membrane and inhibiting kinesin upon hydrolysis
by intracellular esterases. The structure of positions 1–10 in 1 seems
to have little impact on activity. For example, 1 resembles a linear
version of 4. Despite dramatic steric consequences, 4 and 1 exhibit
comparable activities. The ring system of 3 differs from the ring
systems of most other adociasulfates in the position of its axial
methyl groups but still exhibits trans geometries across all ring
junctions. The absence of the pentacyclic ring linking the aromatic
system to the adociasulfate core does not result in reduced activity,
suggesting that some degree of conformational freedom of the ar-
omatic ring is tolerated. Thus, our ﬁnding that 3 is also a strong
kinesin inhibitor reinforces the idea that the broader meroterpenoid
hydroquinone class of compounds may affect kinesin activity. Com-
pounds from the extended family [e.g., disidein (21), haliclotriols
(22), and ﬂabellinol (23)] should be tested for their effect on
kinesin activity in the future.
We note that a modiﬁed steroid core coupled to a benzene
ring is a common feature of most of the strongest known ado-
ciasulfate inhibitors of kinesin (including 1 and 2). Because the
most variable structural features of adociasulfates do not seem to
affect kinesin inhibition, we reason that the benzylated sterol
core is responsible for the observed activity. Compounds 1, 4,
and 7 are strong kinesin inhibitors and share this motif with 5.
Thus, it is likely that 5 is also a kinesin inhibitor and should be
tested for such bioactivity. The steroid nucleus is a common
chemical skeleton and not likely responsible for kinesin inhibition
by itself. Indeed, our measurements show no notable kinesin in-
hibitory activity for cholesterol—a sterol lacking a benzene ring.
There is, however, a lack of true SAR data surrounding the core,
and additional exploration of the adociasulfate motif is necessary.
We ﬁnd no evidence to support the presence of extended in-
hibitory aggregates of the adociasulfates in kinesin assays. We
did not observe free-ﬂoating extended aggregates as described in
the work by Reddie et al. (16) through differential interference
contrast (DIC) imaging. We examined whether smaller aggre-
gates might be present on beads using bead diffusion assays with
functional kinesin-1 preadsorbed to the beads. Kinesin was fully
capable of MT binding and therefore, also capable of interacting
with any aggregates acting as MT mimics. The random attachment
of extended structures to spherical beads typically increases the
effective Stokes radius of the beads and hence, lowers the bead
diffusion coefﬁcient. We observed no difference in bead diffu-
sion between assays with and without 15 μM 1 (Fig. 2B). We did
observe lower diffusion for beads preincubated with short
microtubules (Fig. 2B), indicating that our measurements were
sensitive enough to detect micrometer-long aggregates on beads.
Finally, our single-molecule biophysics experiments provide evi-
dence that even nanoscale aggregates are not needed for kinesin
inhibition. In single-motor assays (bead binding fraction below
30%), bead binding to MTs resulted in kinesin stepping in the
absence of adociasulfates but failed to produce subsequent mo-
tility on incubation with 1.
Although MT binding is inhibited by adociasulfates, binding
events still occur to a small extent, implying that at least one
head of the kinesin-1 dimer is available to bind MTs. However,
the stepping motion after the initial MT binding event is notably
inhibited. Because adociasulfate activity is thought to result from
the compound binding to the kinesin head, we conclude that the
unattached head is bound by 1, halting the processive motion of
kinesin. It is tempting to speculate that the mode of inhibition of
stepping occurs by either blocking the binding of the adocia-
sulfate-bound head to the MT or sterically preventing the un-
attached head from passing the MT-bound head, thus blocking
the powerstroke-induced isomerization of the kinesin dimer.
Regardless of the exact mechanism, we conclude that, under our
assay conditions, adociasulfates can bind a single head of a
kinesin dimer without inhibiting the second head of the dimer
(either sterically or allosterically).
Fig. 3. Eg5 and BimC inhibition by AS-13. (A) The motor domains of BimC and Eg5 are highly homologous, particularly the region containing their MT
binding sites (green box). BimC has a unique N-terminal domain that has independent MT binding activity (red box) (20). Clustal Omega (European Molecular
Biology Laboratory-European Bioinformatics Institute) was used for alignment. Clustal Omega consensus symbols are shown to indicate degree of residue
similarity (28). (B) Binding of Eg5, BimC, and KIF5A is inhibited by AS-13 (1). The ratio of binding afﬁnities was directly estimated in parallel assays with and
without 1 (1.87 ± 0.10 for Eg5 and 2.66 ± 0.14 for BimC; three independent measurements for Eg5 and BimC). The relative KIF5A–MT afﬁnities (as well as
corresponding error bars) were computed as described in Fig. 2. Higher ratio indicates stronger binding inhibition by 1.




































The failure of adociasulfates to cross-link kinesin heads is not
limited to the two heads of the same dimer. Beads precoated
with kinesin-1 motors are not cross-linked in the presence of
15 μM of any adociasulfate that we have tested. However, sim-
ilarly prepared beads are, indeed, efﬁciently cross-linked by
microtubules in solution in the absence of ATP, consistent with
previous observations of multiple kinesins binding or even
densely covering the same MT (Fig. S8B) (24, 25). Based on the
above evidence, we propose that aggregate formation is not
a factor in adociasulfate inhibitory activity and that kinesin in-
hibition by adociasulfates needs to be considered on the scale
of an individual MT binding domain.
We examined whether MT binding domains other than the
motor head domain of kinesin are affected by adociasulfates. We
compared MT binding of Eg5 and BimC, the latter of which has an
N-terminal nonkinesin MT binding domain. We found that MT
binding of BimC is inhibited by 15 μM 1 to a greater extent than
Eg5. Thus, in the presence of 1, the N-terminal domain of BimC
does not enhance its binding to MTs. This result suggests that MT
afﬁnity of both MT binding domains of BimC is inhibited by ado-
ciasulfates. The interaction of the N-terminal domain with MTs is
largely electrostatic and could be efﬁciently screened by the nega-
tively charged adociasulfates, resulting in greater relative inhibition
of binding for BimC. The exact mechanism by which adociasulfates
affect the activity of the N-terminal domain of BimC requires ad-
ditional investigation, but the result directly shows that MT binding
activity of domains other than the one found in kinesin family
motors may be affected by adociasulfates. Therefore, future drug
discovery efforts based on adociasulfates and related structures
need to screen broad effects on MT-associated proteins rather than
conﬁne their focus to kinesins.
In conclusion, our work has shown that AS-8 (3), AS-13 (1),
and AS-14 (2) inhibit kinesin MT binding as well as the processive
motion of kinesin. The ability of 2 to inhibit kinesin indicates that
glycolic acid may be substituted for a sulfate without a signiﬁcant
loss in activity. Thus, the possibility exists that other functional
groups can be used to effectively replace sulfates and enhance
the drug-like properties of adociasulfates. The absence of visible
small molecule aggregations and the lack of detectable cross-
linking between kinesin-bound beads suggest that single mole-
cules of adociasulfates bind individual kinesin motors, enhancing
their potential as subjects of future drug development. Moreover,
both mitotic and nonmitotic kinesins are inhibited, expanding the
range of possible therapeutic targets (13, 14). Work by Brier et al.
(13) provided evidence that adociasulfates are useful as molec-
ular probes to understand kinesin activity. The observation that
mitotic and nonmitotic kinesins tend to be inhibited to a different
extent not only has therapeutic implications but also makes
adociasulfates intriguing tools for future in vitro experiments. The
broad range of potential adociasulfate targets is in contrast to the
mechanism of monastrol, which is speciﬁc for the mitotic kinesin
Eg5, further enhancing the versatility of adociasulfates as mo-
lecular probes (3). Finally, widespread kinesin inhibition by this
family of compounds, despite structural variability, implies that
additional related compounds may be active. In particular, AS-9
(5) and AS-10 (6) are likely kinesin inhibitors. We base this
prediction on the presence of the benzylated sterol-like core in
many of the most active adociasulfates. Investigation of the SAR
of this motif would require synthesis and derivitization of the core
or use of different or novel merotriterpenoids in kinesin assays.
Methods
General Experimental Procedures. Optical rotations were measured using
a PerkinElmer Model 343 Polarimeter set at 589 nm and 20 °C with a 5.0-s
integration time and a 1-dm path length cell. UV spectra were obtained
using a Hitachi U-4100 spectrophotometer. NMR spectra were recorded on
a Varian INOVA 600 NMR spectrometer (1H 600 MHz, 13C 150 MHz) equipped
with a 5-mm Nalorac IDTG probe with a z-axis gradient or a Varian INOVA
500 NMR spectrometer (1H 500 MHz, 13C 125 MHz) using a 3-mm Nalorac
MDBG probe with a z-axis gradient. Residual solvent signals were used for
referencing (δH = 2.50 ppm, δC = 39.52 ppm for DMSO-d6 and δH = 4.87 and
3.31 ppm, δC 49.15 ppm for CD3OD). Liquid chromatography–MS analyses,
including high-resolution mass spectra, were recorded using a Waters
Micromass Q-TOF Micro mass spectrometer in negative ion mode with ion
source and desolvation temperatures of 100 °C and 400 °C, respectively, and
desolvation with nitrogen gas at a 400-L/h ﬂow rate. A Beckman System
Gold 126 solvent module with a 168 PDA detector was used for analytical
and semipreparative HPLC. All reagents were purchased and used without
additional puriﬁcation.
Biological Material. Sponge material identiﬁed as C. aculeata Pulitzer-Finali,
1982 (order Haplosclerida, family Chalinidae) was collected by scuba from
Eastern Fields, Papua New Guinea (S 10°00.395′; E 145°43.924′) and imme-
diately frozen. A voucher specimen is maintained at the University of Utah
under accession number PNG11-17–127.
Extraction and Isolation. Frozen sponge (190 g wet mass) was extracted three
times with MeOH. Pooled extracts were fractionated on Diaion HP20SS resin
using isopropanol (IPA)/H2O mixtures in 25% (vol/vol) increments followed
by a 100% MeOH wash to generate ﬁve fractions with a cumulative mass of
1,314.6 mg. A portion of the F1 fraction (25/75 IPA/H2O; 203.9 mg) was
subjected to C18 ﬂash chromatography eluting with MeOH/H2O in 15% steps
from 40% to 100% MeOH to generate 24 fractions. Fractions C–H were
combined, yielding 56.7 mg material, and further fractionated by HPLC us-
ing a Luna 5μ C18 column (100 Å, 250 × 10 mm) and a 1%/min linear gradient
from 45% acetonitrile (ACN) to 70% ACN with 0.2 M NaCl. Salt was removed
by loading samples onto preequilibrated Waters SEP-PAK C18 cartridges and
ﬂushing with three column volumes of 10% MeOH followed by elution of
desired compounds with 100% MeOH. A broad peak eluting from 10 to 12.5
min (21.5 mg) was subjected to a ﬁnal HPLC fractionation using a Luna 5μ
pentaﬂuorophenyl column (100 Å, 250 × 4.6 mm) and an isocratic solvent
method at 76%MeOH/24% 0.2 M NaCl yielding compounds 1 (tR = 10.0 min,
5.5 mg), 3 (tR = 12.0 min, 6.9 mg), and 2 (tR = 15.0 min, 2.3 mg).
Adociasulfate-13 (1).White solid; [α]20D –21.7 (c 0.55, MeOH); UV (MeOH) λmax
(log e) 220 nm (3.93), 265 (2.47) nm; 1H and 13C NMR (Table S1); high-resolution
electrospray ionization mass spectrometry (HRESIMS) m/z 709.3102 [M–H]–
(calculated for C36H53O10S2, 709.3086; ∆ −2.3 ppm).
Adociasulfate-14 (2). White solid; [α]20D –42.9 (c 0.13, MeOH); UV (MeOH) λmax
(log e) 220 nm (3.86), 266 (2.60) nm; 1H NMR and 13C NMR (Table S2); HRESIMS
m/z 687.3553 [M–H]– (calculated for C38H55O9S, 687.3572; ∆ 2.8 ppm).
Protein Material. BimC from Aspergillus nidulans and human Eg5 was pur-
chased from Cytoskeleton. Human kinesin-1 (KIF5A heavy chain) with C-
terminal 6xHis and FLAG tags and an N-terminal maltose-binding protein
(MBP) tag was bacterially expressed in BL21DE3. The strategy of using an
MBP solubility tag on the N terminus follows the work by Wong and Rice (26)
and allowed us to successfully express high quantities of nonaggregated full-
length KHC. Lysis was accomplished by sonication for 30 min at 4 °C. Lysis
buffer: 50 mM sodium phosphate, pH 7.8, 300 mM NaCl, 10% glycerol, 20 mM
imidazole, 2 mM MgCl2, 0.25 mM ATP, 2 mM bME, and 0.2 μM PMSF with
EDTA-free Roche mixture inhibitors. Cell lysis was followed by immobilized
metal ion afﬁnity chromatography puriﬁcation (two washes and elution).
Wash buffer 1: 50 mM sodium phosphate, pH 7.8, 500 mMNaCl, 10% glycerol,
40 mM imidazole, 0.02% Triton X-100, 2 mMMgCl2, 0.25 mM ATP, and 2 mM
bME. Wash buffer 2: 50 mM sodium phosphate, pH 7.8, 300 mM NaCl, 10%
glycerol, 100 mM imidazole, 2 mM MgCl2, 0.25 mM ATP, 3 mM glutathione
(GSH), and 0.3 mM glutathione disulﬁde (GSSG). Elution buffer: 50 mM so-
dium phosphate, pH 7.5, 300 mM NaCl, 5% glycerol, 500 mM imidazole, 2 mM
MgCl2, 0.25 mMATP, 3 mMGSH, and 0.3 mMGSSG. Material was then loaded
on an anti-FLAG column. Equilibration buffer: 50 mM Tris·HCl, pH 7.5, 300 mM
NaCl, 15% glycerol, 0.005% Triton X-100, 2 mM MgCl2, 0.25 mM ATP, 3 mM
GSH, and 0.3 mM GSSG. Cleavage of the N-terminal MBP tag was per-
formed using TEV protease on the same column. Elution buffer: 50 mM
Tris·HCl, pH 7.5, 300 mM NaCl, 15% glycerol, 0.005% Triton X-100, 2 mM
MgCl2, 0.25 mM ATP, 3 mM GSH, 0.3 mM GSSG, and 0.1 mg/mL 3× FLAG
Peptide. Gene synthesis of KIF5A and puriﬁcation were performed by
Bionexus, Inc.
In Vitro Motility Assay. In vitro motility assays were prepared at room tem-
perature. Flow cells were prepared by attaching a clean poly-L-lysine–coated





coverslip to a glass slide using double-sided tape. Assay buffer was PMEE
(35 mMPipes, 5 mMMgCl2, 1mM EGTA, 0.5 mM EDTA), pH 7.2. Taxol-stabilized
MTs were ﬁrst diluted in ﬂow buffer (assay buffer + 20 μM taxol + 1 mM GTP)
and then rapidly ﬂown into the ﬂow cell so that they were typically ﬂow-
aligned and attached to the polylysinated surface parallel to each other. After
a brief incubation, mobile MTs were washed away, and the surface was blocked
with buffer containing 20 mg/mL casein (Sigma-Aldrich).
Kinesin-1 at a selected concentration was ﬁrst incubated for 10 min at
room temperature with carboxylated polystyrene beads (1-μm diameter;
Polysciences, Inc.) in the presence of saturating ATP (1 mM ATP). The se-
lected adociasulfate stock solution (1.5 mM adociasulfate in DMSO) was ﬁrst
diluted 10-fold in assay buffer and then added to the kinesin bead mixture
for a ﬁnal adociasulfate concentration of 15 μM. The mixture was then in-
cubated at room temperature. Incubation times did not affect the observed
results. Typical incubation lasted 15 min. On incubation, the mixture was
admitted into the ﬂow cells.
Measurement of Binding.Optical trapping experiments were performed using
a previously described measurement setup (27). Brieﬂy, beads and MTs were
viewed using an inverted DIC microscope (Nikon Eclipse Ti-U) equipped with
a high-magniﬁcation, high-NA objective (Nikon Plan Apo VC 100× oil, 1.40
NA). A high-resolution camera (Andor iXon+ DU897) and Nikon NIS ele-
ments AR 3.1 software were used to record experiments. Custom-built image
processing and tracking software written in Matlab (Mathworks) was used
for video tracking. Additional analysis and ﬁtting were performed using
Origin software (Orginlabs).
To measure the fraction of beads bound by kinesin, a bead was optically
trapped (∼4 mW laser power at the sample) and moved close to MTs. After
a testing period of at least 40 s, beads that exhibited no MT binding were
scored as such.
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CHEMICAL DIVERSIFICATION ENABLES SYMBIOTIC MICROBIOTA TO  
 




 The microbiota is thought to provide host animals with bioactive metabolites, 
such as antibiotics and other forms of chemical defense. Here, we show how chemical 
diversification in the microbiota of marine tunicates leads to functionally distinct 
secondary metabolites, resembling a “call-and-response” type adaptation. Small colonial 
tunicates of the species Didemnum molle contained a family of structurally novel 
peptides, some of which exhibited anti-HIV effects. By marrying structure elucidation, 
whole microbiota sequencing methods, and synthetic biology, we uncovered the 
divamide family of natural products. The anti-HIV compound divamide A and 
derivatives were synthesized recombinantly using Escherichia coli, eliminating the need 
to harvest large amounts of animals from coral reefs for chemical and pharmacological 
evaluation. The ensuing structure-activity studies revealed a sequence-specific 
requirement for the potent anti-HIV activity observed within the divamide series. These 
results reveal how small animals, enabled by their microbiota, may achieve new or 
modified functions through simple changes in protein sequence. In this way, chemical 
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diversification may reflect a weapon in the evolutionary arms race between the tunicate 
symbiosis and its environment. 
 
3.2 Introduction 
Chemistry guides the interactions between living organisms. Natural chemical 
diversity directs the specificity of these interactions and structures communities. An 
individual species or strain is commonly thought to display a distinctive chemical profile 
that reflects its particular role or function within the biological community. However, in 
certain situations organisms utilize biosynthetic pathways that inherently produce diverse 
chemicals, establishing populations of similar individuals with variable chemistry. This 
phenomenon is repeated throughout nature, indicating an evolutionary advantage of 
displaying chemical variability. A potential role of chemical diversity is to generate 
functional diversity. Chemical diversity enables adaptation to a changing environment, 
allowing either existing functions, perpetrated by chemicals, to be modified or new 
functions to be obtained. This may play a role in competition between species. Such 
properties would be useful from a medicinal chemistry perspective for the design of new 
and effective drugs in an era of increasing resistance.  
Here, we show that the flexibility of a single biochemical pathway leads to useful 
functional differences that can be applied to treating human disease. From a remote reef 
in the Coral Sea, we found small colonies of tunicates containing related lanthipeptides 
for which minor structural variations result in major functional differences. We used a 
new approach integrating organic chemistry, metagenome sequencing, and synthetic 
biology to discover, produce, and characterize the biological action of a series of novel 
anti-HIV compounds: the divamides. We show that these compounds are produced by 
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uncultivated symbiotic bacteria that generate diverse chemicals using a highly conserved 
biosynthetic pathway and use this knowledge to produce two natural analogs using a 
single set of enzymes. 
 
3.3 Results 
We identified the organic extract from a small marine tunicate, Didemnum molle 
(E11-036) from Papua New Guinea, as a promising lead in an anti-HIV assay (Figure 
3.1-A, left). The active compound, divamide A, was purified (<1 mg) by bioassay-guided 
fractionation and determined to be the active component (Figure S3.1). Using 
spectroscopic methods, divamide A was determined to be a novel peptide containing the 
modified amino acid lanthionine (Lan), and its partial sequence was elucidated. However, 
because of the limited available material, the structure could not be completed. Therefore, 
we turned to metagenome sequencing as a novel method for chemical discovery. 
DNA was extracted from macerated tissues of the whole animal, sequenced, and 
assembled. The putative tetramer “GTTR” was used to probe the assembled metagenome, 
yielding a hit to a short coding sequence (CDS) for a precursor peptide (divA) from a 
ribosomally and posttranslationally modified peptide (RiPP) biosynthetic pathway (Table 
S3.5).1 The 20 C-terminal residues of DivA encompassed the divamide A amino acids 
predicted by NMR as well as the sequence “GTTK,” suggesting the Arg residue of the 
anticipated sequence was misinterpreted from NMR data. Immediately adjacent to divA 
was a gene (divM) bearing homology to the type II lanthionine synthetases,2 confirming 
the lanthipeptide association. In addition, a series of other genes was predictive of the 
divamide A structure. Divamide A incorporates three methyllanthionine residues 
(MeLan), lysinoalanine (Lal), ß-hydroxy aspartic acid (Hya), and N-terminal 
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trimethylation, a rare posttranslational modification in nature (Figure 3.1-B).3-5 Thus, a 
traditional bioassay-guided natural products approach was integrated with metagenomics-
based methods to easily elucidate the structure of an otherwise highly challenging 
compound. Finally, with the planar structure in hand, stereochemical analysis was 
performed using chemical degradation. 
A second, morphologically distinct D. molle specimen (E11-037) was collected in 
the same location as E11-036 and its extract exhibited no anti-HIV properties (Figure 
3.1-A, right; Figure S3.1). Several divamide-like peptides were identified in the E11-
037 extract including divamides B and C, but only divamide B could be fully 
characterized by the same spectroscopy-metagenome methodology used for divamide A 
(Figures S3.4, S3.5). All of the same posttranslational modifications adorn these 
compounds, which differ from divamide A only in amino acid sequence (Figure 3.1-C). 
Metagenomic analysis revealed a nearly identical biosynthetic gene cluster to that of 
divamide A, although only a partial sequence was recovered due to the challenging nature 
of the sample (Figure 3.1-D, Table S3.5). 
The lack of any anti-HIV activity in divamide B or C starkly highlights how 
modest changes in structure govern the pharmacology. We sought to determine the 
molecular basis for this disparity and to provide material to determine the mechanism of 
action of divamide A. Given the scarcity of isolated material, we first aimed to produce 
divamides by recombinant expression. Such an in vivo total synthesis could also be used 
as a structural confirmation. Finally, it would represent the first example of a new 
strategy for drug discovery, marrying the best of traditional natural products chemistry 
with tools of metagenomics and synthetic biology. 
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The div clusters were found embedded not in the genomes of the host animal, but 
in those of symbiotic cyanobacteria, Prochloron didemni.6 P. didemni often produces 
bioactive, presumably defensive chemicals in the interior of tunicates,7 but lanthipeptides 
were previously not known. The div cluster is comprised of genes encoding five 
biosynthetic proteins, an export pump, and two genes of unknown function. In addition to 
divA and divM, these include an a-ketoglutarate-dependent Fe(II) monooxygenase ß-Asp 
hydroxylase (divX), a homolog of the uncharacterized cinorf7 thought to be involved in 
lysinoalanine formation (divLA),8 a SAM-dependent methyltransferase (divMT), and an 
ABC-type transporter (divT). Our expression strategy aimed to use these biosynthetic 
genes to reconstitute synthesis in Escherichia coli. However, the source organism is 
highly problematic for cloning experiments, being rich in mucopolysaccharides, and 
compounding the problem P. didemni was relatively rare in the samples and intractably 
embedded in animal mucus. 
Therefore, we synthesized the expression vector by codon optimizing the 
biosynthetic genes and using native coding sequences in the intergenic regions, then 
placing the whole artificially organized operon under control of lac (Figure 3.2-A). This 
initial vector yielded no detectable products. Through a series of trials, we found that 
replacement of codon-optimized divM with the native gene sequence (shown in black), 
amplified from metagenomic DNA (Figure S3.6), resulted in production of divamide 
intermediates with three MeLan residues and dehydroalanine (Dha) but lacking Lal and 
methylation (Figure 3.2-A, step 1). While the 20-mer peptide was detected as a major 
product of the pathway, peptides of one, two, and three residues longer were also 
observed, reflecting cleavage at four different positions within the putative recognition 
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site “DIAA” (Figure S3.8). This implies the existence of an E. coli protease capable of 
performing a similar function as that of a symbiotic cyanobacterial protease. As the div 
and other lanthipeptide pathways lack a designated protease,2 this observation is 
particularly interesting in the context of heterologous expression. 
To complete the synthesis of divamide A from the desmethyl deslysinoalanine 
intermediate, Lal was introduced in vitro, forming spontaneously under basic conditions 
as described for cinnamycin (Figure 3.2-B, step 2).8 DivMT, expressed and purified 
from E. coli BL21(DE3) (Figure S3.7), was unable to accept deslysinoalanine 
intermediates as a substrate, catalyzing N-terminal trimethylation only after introduction 
of Lal and only on the 20-mer substrate (Figure 3.2-B, step 3). The stringency of DivMT 
substrate specificity suggests that nonenzymatic Lal formation is stereoselective, likely 
due to structural constraints imposed by the prior installation of three MeLan residues. 
From our synthesis of divamide A, a functional role could be assigned to all biosynthetic 
genes in the pathway except divLA (Figure 3.2-C). 
Scale up of this initial process involved several improvements, the most notable 
of which was adding cysteine to the expression media. As previously found in work with 
cyanobactin RiPP products, cysteine significantly improved the in vivo production of 
divamide A.9 Currently, the best method produces 13.7 µg deslysinoalanine derivative 
per L of E. coli culture broth, after purification to homogeneity. From about 90 L of 
culture, 157 µg of pure divamide A were obtained. This represents a 12.7% yield from 
the delysinoalanine divamide A. Accurate measurement of submilligram quantities 
required the use quantitative NMR or LC/MS (Figures S3.9, S3.10; Tables S3.6, S3.7). 
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NMR analysis confirmed that the synthesized divamide A was identical to the natural 
product, confirming the elucidated structure (Figures 3.2-D, S3.11). 
With material now in hand, we evaluated the biological activities of the divamides 
and their biosynthetic intermediates alongside cinnamycin, a closely related lanthipeptide 
produced by the soil-actinobacterium Streptomyces cinnamoneous.10 Human CEM 1a2 
tat/rev++ T-cells were incubated with compound and infected with vIIIB∆Tat/Rev HIV 
pseudovirus. Cell survival was determined four days after infection using a colorimetric 
MTT assay.11 Potent cytoprotective activity was observed for both original and synthetic 
divamide A, as well as desmethyl divamide A, the desmethyl extra-proteolytic divamide 
A species, and an uncharacterized methyl ester of divamide A (Figure 3.3, Figure 
S3.12). This activity was absent, however, for deslysinoalanine divamide A, divamide B 
and cinnamycin. Additionally, significant cytotoxicity was observed for all but one 
divamide compound at concentrations just 10-fold higher than cytoprotection IC50 values, 
indicating a relatively narrow therapeutic window. Cinnamycin displayed the most potent 
cytotoxicity, consistent with previous reports of its hemolytic and pro-apoptotic 
properties.12-13 Interestingly, divamide C, an uncharacterized lanthipeptide isolated from 
E11-037 extracts, exhibited neither cytoprotection nor cytotoxicity. 
These results reveal several key structure-activity relationships. N-methylation is 
not required for anti-HIV activity. Extension of the amino terminus with additional amino 
acid residues did not alter the overall phenotypic effects of divamide, though it appeared 
to slightly widen the therapeutic window of divamide A. Introduction of a methyl ester, 
likely at either the Glu or Hya side-chain carboxylic acid, also improved this aspect of 
divamide activity. However, the shape of the molecule conferred by MeLan and Lal 
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residues was essential for cytoprotection by divamide A, as is indicated by the loss of 
activity for the deslysinoalanine intermediate. Thus, posttranslational modifications 
outside of the chemical scaffold defined by MeLan/Lal have only minor impacts on the 
overall activity of divamide A. On the other hand, the amino acid sequence has a 
dramatic impact on activity. Five amino acid substitutions between divamide A and B 
lead to the loss of the cytoprotective phenotype for divamide B, highlighting a 
hypervariable region between residues 8 and 14 that is responsible for the cytoprotection 
phenotype. Divamide C displays more sequence substitutions than divamide B while 
maintaining all of the same posttranslational modifications (Figure S3.12), yet it lacks 
any activity at all in the context of this assay. Similarly, the structural differences 
between divamide A and cinnamycin, which mostly reflect changes in sequence, also 
lead to a loss of HIV cytoprotection and enhanced cytotoxicity in cinnamycin. 
Collectively, these observations suggest that while posttranslational modification 
establishes a bioactive scaffold, it is the variation between amino acid sequences that 
determines the biological activities of the divamides. 
Divamides A-C do not provide a complete picture of the chemical diversity within 
the tunicates described. While only two peptides were isolated in purity from E11-037, a 
number of other divamide-like ions were observed by LC/MS to display Hoffman 
elimination of trimethylamine,14 a characteristic of divamides possessing N-terminal 
trimethylation (Table S3.8, Figure S3.13). Still other species were observed resembling 
divamide but lacking N-trimethylation, likely representing partially or nonmethylated 
intermediates. This is distinct from E11-036, from which a single divamide was observed 
and whose metagenome contains a single div pathway and precursor gene. Only one 
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precursor gene encoding divamide B was found for E11-037 due to the challenging 
nature of the sample, but the presence of additional divamides with alternative amino acid 
sequences implies the presence of multiple gene clusters or precursors. Lanthipeptide 
pathways from other organisms were identified by BLAST search that exhibit multiple 
precursor genes per cluster, or multiple clusters per genome (Figure S3.14). In addition, 
some of these pathways display the potential for novel posttranslational modifications not 
found in related but characterized pathways. An alignment of precursor protein cores 
indicates a signature chemical scaffold consisting of Lan, Lal, Hya, and Gly residues, 
while most residues in between these conserved positions are highly variable (Figure 
S3.15). Thus, there exists convincing evidence to suggest that the div pathway and its 
extended lanthipeptide family encompass a broader family of peptides that is chemically 
diverse within a conserved scaffold. 
 
3.4 Discussion 
This work represents the first example of a direct discovery-supply strategy of a 
symbiotic natural product. Prior knowledge of the compound’s biological activity and 
structure obtained via a bioassay-guided approach greatly facilitated pathway 
identification from a complex metagenome, enabling access to novel chemistry. A 
compound of such limited sample size would likely be abandoned in the context of a 
traditional natural products approach, while the organism would not have been targeted 
for metagenome mining without significant cause, such as promising biological activity 
or unique chemistry. The discovery process also provided us with a platform to produce 
divamides biosynthetically. We have already synthesized more divamide than was 
originally isolated from the natural source. 
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Nature uses chemical diversity to obtain functional diversity. This ability is highly 
prized by medicinal chemists seeking to discover new drugs. Nature is particularly adept 
at creating complex, biologically relevant chemical scaffolds, but also excels at 
incorporating diversity into these scaffolds using simple biochemical concepts. This is 
especially true for natural products. The div pathway exhibits elements of diversity-
generating RiPPs, including broad-substrate enzymes and precursor gene divergence,15 
but lacks the conformational and scaffold diversity displayed by the prochlorosins or 
cyanobactins.16-17 Nonetheless, internal amino acid changes have dramatic effects on 
divamide activity. The divamide scaffold may be particularly well suited for biological 
interactions, or this may reflect fine-tuning of a conserved function, perhaps in response 
to similar adaptability in the native target. Such a “call-and-response” is reminiscent of 
elements of the innate immune response and may be well suited to deal with viruses.18 
 
3.5 Supplementary results 
Divamide A was isolated from E11-036 as a white powder with m/z 1010.96248 
[M+H]2+, determined by Fourier transform mass spectrometry (calculated for 
C87H139N21O28S32+, 1010.96299; ∆ -0.504 ppm). A 1H NMR spectrum recorded in D2O 
revealed amino acid-like chemical shifts (Figure S3.2-A). Homonuclear (gCOSY, 
zTOCSY, ROESY) and heteronuclear (gHSQC, gHMBC, gHSQCTOXY) experiments 
conducted in the same solvent led to the identification of individual amino acid spin 
systems, including Gly, Ala, Val, Ile, Phe, Arg, Thr, and Ser (Figure S3.2-B–F).  
The presence of several unusual amino acid spin systems was also noted. Hß- Hß 
or HN-Ha NOESY correlations occur between three pairs of Cys-like and Thr-like spin 
systems, suggesting the presence of MeLan (Table S3.2). Additionally, an HMBC 
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correlation was observed from a Cys-Hß to a Thr-Cß that was later determined to 
correspond to Cys15 and Thr5. A residue resembling ß-hydroxy Asp (Hya) displayed a 
strongly deshielded ß-methine (dH 4.75 ppm, dC 73.1 ppm). A prominent heteronuclear 
correlation between dH 3.28 ppm and dC 53.5 ppm appearing in both HSQC and HMBC 
spectra indicated a quaternary trimethylamine functional group, which was associated 
with a Glu residue via NOE correlation between the N-methyl protons and Glu-Ha, and 
via HMBC correlation between N-methyl protons and Glu-Ca. This interpretation was 
supported by the failure of amino acid sequencing by Edman degradation and by 
observation of a characteristic 63 Da mass differential between positive and negative ion 
mode LC/MS spectra resulting from Hoffman elimination of a trimethylamine (Figure 
S3.13).  
Partial amino acid connectivity was determined from either HN-Ha or HN-HN 
NOEs using 2D NMR data acquired in 90% H2O/10% D2O to enable detection of 
exchangeable amide backbone protons. Full deuterium/proton exchange was achieved by 
incubation with 0.1% ammonium hydroxide at 37˚C overnight prior to collection of 
NMR data using protonated solvents. Interpretation of these data resulted in the 
sequences “GTTR” and “AST” (Figure S3.2-H–I). The former was used to search the 
assembled E11-036 metagenome for a RiPP precursor gene using tBLASTn. A short 
CDS was found containing the sequence “ECASTCSFGIVTIVCDGTTK” (divA). The 
gene was clustered with a class II lanthionine synthetase (divM) and other CDSs with 
functional annotations that complied with the modifications predicted. Re-evaluation of 
NMR data showed complete agreement with the sequence, indicating an incorrect 
assignment of the Lys spin system to Arg and establishing three MeLan linkages between 
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Cys2-Thr19, Thr5-Cys15, and Cys6-Thr12. The sequence and Lan connectivities greatly 
resemble those of cinnamycin, which also incorporates the unusual amino acids Hya and 
Lal. Our data also support the presence of these residues. The presence of Lys instead of 
Arg made obvious an NOE between Lys20-He and Ser7-Hß indicative of Lal. A 13C 
spectrum obtained using 500 MHz instrument with a carbon-optimized cryogenic probe 
included 87 carbons (Figure S3.2-K), though not all could be assigned due to the absence 
of HMBC signals for those carbons. Additional 2D experiments, collected in 70% 
CD3OH/ 30% H2O/ 0.1% TFA using a 900 MHz spectrometer to improve the separation 
between amide proton signals and enhance signal-to-noise, agreed with previous data 
(Figure S3.2-J–M). Thus, the planar structure of divamide A was elucidated partly by 
spectroscopy and partly using metagenomics. 
Stereochemical characterization of divamide was accomplished by degradative 
analysis. Mixtures of amino acid standards were subjected to acid hydrolysis, esterified 
with methanol, and then amidated using pentafluoropropionyl anhydride. These were 
subjected to chiral GC/MS alongside similarly treated divamide A for comparative 
analysis of retention times and fragmentation patterns (Table S3.3). All conventional 
amino acids were detected in L configurations, while atypical amino acids L-erythro-
Hya, D-L MeLan, and L-L Lal exhibited identical chirality to cinnamcyin (Figure S3.3). 
Lal standards (LL and DL) were run on an achiral GC/MS column. In the course of 
divamide A hydrolysis, some scrambling of the Lal configuration was observed. The 
residual excess of the LL enantiomer indicated the initial Lal configuration was LL. The 
formation of Lan and MeLan results in inversion of the relative Ca configuration of the 
recipient Ser or Thr residue. This is distinct from Lal, in which no change in 
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stereochemistry occurs. The configuration of N-trimethylglutamate is most likely to be L 
based on overlapping NOEs with biosynthetic divamide A (Figure S3.11-G). 
Divamide B was isolated from E11-037 as a white powder with m/z 965.9194 
[M+H]2+ by high-resolution electrospray ionization mass spectrometry (HRESIMS) 
(calculated for C79H129N21O29S32+, 965.921325; ∆ 1.99 ppm). Hoffman elimination, 
observed by LC/MS, suggested similar posttranslational modifications as found in 
divamide A (Figure S3.13). NMR data recorded in either 70% CD3OD/ 30% D2O/ 0.1% 
TFA or 70% CD3OH/ 30% H2O/ 0.1% TFA revealed many overlapping spin systems 
with divamide A as well as some significant differences (Table S3.1, Figure S3.4). 
While no Val was detected, Ala and Pro spin systems were recognized. Two Ile spin 
systems were identified that differed significantly from those of divamide A, suggesting 
alternative positions. Two sets of correlations were observed in homonuclear spectra for 
most divamide B spin systems. This can be explained by the potential for conformational 
isomerization introduced by Pro. The reported chemical shifts are similar to those of 
divamide A and represent the major divamide B rotamer. A precursor protein containing 
the sequence “ECASTCSSGPITAICDGTTK” was identified from a partial div cluster 
found in the assembled E11-037 metagenome. The predicted lanthipeptide of this 
pathway, containing modifications identical to divamide A, fit well with the observed 
mass and NMR data. Some controversy exists regarding the presence of aromatic 
chemical shifts despite the apparent replacement of Phe8 with Ser. However, expression 
of pDiv2 in E. coli using the divamide B core with the divamide A biosynthetic enzymes 
resulted in production of m/z 944.9, the predicted mass of desmethyl divamide B, as well 
as the same extra-proteolytic species that were observed with divamide A expression 
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(Figure S3.8-B). These data suggest that the precursor protein sequence from E11-037 is 
the correct divamide B sequence.  
Divamide C was isolated from E11-037 as a white powder with m/z 1039.4535 
[M+H]2+ by HRESIMS. Similar to divamide B, Hoffman elimination in negative ion 
mode was observed, suggesting a relationship to divamide A (Figure S3.13). 2D NMR 
data were difficult to interpret due to a low signal-to-noise ratio, but conserved residues 
of divamides A and B were observed (Figure S3.5-B–E, G–I). No additional precursor 
genes or div clusters were identified from E11-037, preventing us from obtaining an 
amino acid sequence to aid in structure elucidation. In an attempt to predict the sequence, 
we used the online tool Mass Analysis Peptide Sequence Prediction (MAPSP) to generate 
a list of all possible peptide masses that could be obtained given a number of sequence 
restrictions (http://mapsp.ifg.uni-muenster.de).19 From an alignment of all related 
divamide precursor proteins, eight variable positions become readily apparent (Figure 
S3.15). We limited the number of responses by allowing only those residues known to 
occur in these positions. Even with these restrictions, we obtained 722 possible sequence 
masses that occur within 5 ppm of the accurate mass obtained for divamide C. However, 
NMR spectra suggest that divamide C resembles divamide B in the presence of Pro10- 
and Ile14-like spin systems, but incorporates a Val11-like residue akin to that in divamide 
A (Figure S3.5-C). Imposing these additional restrictions reduces the number of possible 
sequences to 12. The sequence ECQSTCSYGPVTVICDGTTK best fits all available data 
(calculated for C88H138N22O30S32+, 2078.91105; ∆ 1.95 ppm), but could not be confirmed 
using spectroscopic or genomic techniques. 
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A putative degradation product of divamide A that was 14 Da higher in mass 
accumulated in the original E11-036-derived divamide A material over a period of more 
than one year, such that the +14 Da derivative contributed significantly to the overall 
mass ratio (Table S3.7). This peptide mixture displayed a wider therapeutic window than 
pure divamide A by HIV cytoprotection assay, suggesting the derivative may exhibit 
improved pharmacological properties (Figure 3.3). The +14 Da species was identified by 
HRESIMS as the methylation product of divamide A (calculated for C88H141N21O28S32+, 
1017.9708; ∆ 1.38 ppm). Though the exact methylation position was not determined, it is 
possible that either of the two acidic residues Glu or Hya or the C-terminus was esterified 
with methanol during deuterium back-exchange in 0.1% ammonium hydroxide.  
 
3.6 Methods 
3.6.1 General. The majority of NMR spectra were recorded on a Varian INOVA 
600 NMR spectrometer (1H 600 MHz, 13C 150 MHz) equipped with a 5 mm Nalorac 
IDTG cryogenic probe or a Varian INOVA 500 NMR (1H 500 MHz, 13C 125 MHz) with 
5 mm Nalorac IDTG probe, using residual solvent signals for reference (δH = 4.80 ppm 
for D2O and δH = 4.87 ppm, δC = 49.15 ppm for D2O/CD3OD mixtures). For the initial 
structural characterization of divamide A, a Bruker Advance III HD 900 MHZ instrument 
(1H 900 MHz, 13C 225 MHz) with 5 mm 1H(13C/15N) cryogenic probe and a Bruker 
Advance III 500 MHz (1H 500 MHz, 13C 125 MHz) with a 5 mm 13C/15N(1H) cryogenic 
probe were also used. Liquid chromatography–MS spectra were recorded using a 
Micromass Q-ToF Micro mass spectrometer (Waters). High-resolution mass spectra were 
recorded on a LTQ-FTMS (ThermoElectron) or a maXis-II ETD Q-ToF (Bruker). 
Analytical HPLC was performed on a Beckman System Gold 126 solvent module with a 
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168 PDA detector or a Hitachi Primaide 1110 Pump with 1430 Diode Array Detector. An 
HP 6890 Series GC System equipped with an HP 7683 Series Injector and an HP 5973 
Mass Selective Detector was used for all GC/MS experiments. A Fisher Multiscan FC 
plate reader was employed for biological assays. Amino acid standards included standard 
L and D amino acids (Cyclo Chemical or Sigma-Aldrich), DL-threo-ß-hydroxyaspartic 
acid (Sigma-Aldrich), L-erythro-ß-hydroxyaspartic acid (Wako Chemicals), and DL-
lysinoalanine (Bachem). Methyllanthionine GC/MS standards were generously provided 
by John Vederas (University of Alberta). Cinnamycin was purified from spent culture 
broth of Streptomyces cinnamoneus ATCC 11874 grown in ISP-2 (1L) at 30˚C in 
Fernbach flasks (2.8L) shaking at 150 rpm for three days. 
3.6.2 Animal collection. Tunicates identified as Didemnum molle (Herdman, 
1886) were collected by scuba from the Eastern Fields of Papua New Guinea (S 10˚ 
16.217’; E 145˚ 38.679’). Chemistry samples were immediately frozen, while samples for 
metagenome sequencing were first processed by slicing into or placing small samples in 
Rnalater, then leaving them at 4˚C overnight with occasional inversion of tube, then 
freezing. Vouchers are maintained at the University of Utah under accession numbers 
E11-036 and E11-037, or PNG11-9-099 and PNG11-9-100, respectively.  
3.6.3 Extraction and isolation. Frozen tunicate (200 g) was extracted three times 
in MeOH. Pooled extract was filtered by gravity and fractionated by Diaion HP20SS 
resin using isopropanol (IPA)/H2O mixtures of 25% increments of increasing IPA to 
generate five fractions with a cumulative weight (excluding 100% H2O fractions) of 
581.8 mg for E11-036 and 685.2 mg for E11-037. E11-036 F1 fractions (eluted in 25% 
IPA; 211.3 mg) were subjected to C18 flash chromatography starting at 10% MeOH and 
 82 
increasing stepwise by 30% up to 100% MeOH, yielding eight fractions. Fraction E (70% 
MeOH; 19.1 mg) was further fractionated by HPLC. Using a Luna 5µ C18 column (100 
Å, 250 x 4.60 mm) at 1 ml/min, the solvent 30% ACN/70% 0.2 M NaCl was held for 15 
min then increased to 100% ACN over 5 min. Two peaks were collected and desalted 
using Waters SEPPAK C18 cartridges, resulting in divamide A (tR = 8.87 min, 315.1 µg,) 
and oxidized divamide A (tR = 8.09 min, not quantified). A degradation product, later 
identified as a methylated divamide A derivative, accumulated in the divamide A sample 
over time. The resulting mixture was fractionated by C18 using a method similar to that 
described later for lysinoalanine formation, yielding 77.8 µg of pure divamide A and 
237.3 µg of a mixture of the two peptides. 
C18 flash chromatography E11-037 F1 fractions (25% IPA; 172.9 mg) followed a 
similar procedure to generate 12 fractions. Fraction F (40% MeOH, 10.1 mg) was 
subjected to HPLC using the same Luna C18 column at 31% ACN/ 69% 0.2 M NaCl held 
for 11 min then increased to 60% ACN over 4 min and held at 60% for 8 min with a 
1ml/min flow rate, yielding divamide B (tR = 8.78 min). All elutions excluding the pure 
peptide were recombined (7.6 mg) and further purified by HPLC on a Luna 5µ Phenyl-
Hexyl column (100 Å, 250 x 4.60 mm) at 1 ml/min starting at 20% ACN/80% 0.1% TFA 
for 4 min, then increasing to 24% ACN over 4 min and holding for 6 min, increasing to 
30% ACN over 6 min and holding for 3 min, then finally to 60% ACN over 15 min. This 
yielded additional divamide B (tR = 11.45 min, added to divamide B described above for 
a combined weight of 100 µg) as well as divamide C (tR = 20.12 min, 31.7 µg). Reported 
yields were determined by NMR and LC/MS quantification as described below. 
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3.6.4 Quantitative NMR. Quantitative NMR experiments followed previous 
protocols using external standards.20 Samples were suspended in deuterated solvents and 
dried multiple times to ensure full deuterium exchange. A 1:2 dilution series of an L-Trp 
stock solution was prepared in D2O encompassing a range of concentrations from 2.7 to 
0.093 µg/ml to generate a standard curve. These concentrations were obtained by 
measuring UV absorbance using a Nanodrop 2000 (e280, Trp = 5170.9 nm-1, e276, Tyr = 
1322.2 nm-1). Similarly, an L-Tyr standard was also prepared to assess the accuracy of 
the curve. L-Trp and L-Tyr samples were also fully exchanged in D2O prior to data 
acquisition. All samples were then suspended in D2O (120 µl) and transferred to new, dry 
Norell S-3-500-7 NMR tubes. The relaxation time t1 was determined for all proton 
signals intended for quantification and d1 was set to 10 times t1 of the highest observed 
d1. This value, as well as all other parameters, was maintained for all subsequent 
experiments. A 1D 1H spectrum was recorded for each sample and care was given to 
optimize shims between each experiment. Signals of interest were chosen based on 
isolation from other peaks and known proton assignment. Spectra were phased, baseline 
corrected, and integrated, and the absolute integral values were used to produce a 
standard concentration curve (Figure S3.9). Concentrations of samples were calculated 
using the resulting linear equation. To reduce any signal-specific effects, three standard 
curves were generated from three separate L-Trp proton signals and the concentration of 
analyte was calculated from each of them. Similarly, at least two proton signals were 
chosen from each analyte spectrum and the concentrations determined from each L-Trp 
standard curve were averaged. Table S3.6 summarizes the results of quantitative NMR. 
The concentration of L-Tyr was estimated 0.351 ± 0.0095 mg/ml while the UV-
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determined concentration was 0.326 mg/ml. A 7.6% difference was calculated, 
suggesting that analyte concentrations may be slightly overestimated. 
3.6.5 Quantitative LC/MS. A 1:2 dilution series of desmethyl divamide A, 
suspended at the same initial concentration as was determined by NMR (1.935 mM) and 
diluted 100-fold, was prepared to generate a standard curve by LC/MS (Figure S3.10). 
Each sample (100 µl) was spiked with an internal cyanobactin standard (10 µl; m/z 883.5) 
to assess variability in injection volume between each run. Each desmethyl divamide A 
concentration and each analyte were run in triplicate and in random order. The area under 
the curve (AUC) was determined for doubly charged ions in selected ion mode (SIM) for 
all peaks of interest within a sample. Concentrations were calculated from the average of 
the three AUC values. The internal standard AUC fluctuated between runs of like-
samples within two standard deviations (SD = 35.7) of the average AUC (AUC = 132.3), 
or ± ~50%, indicating a moderate degree of run-to-run variability. This was deemed 
acceptable variation given the difficulty in obtaining an accurate mass of small amounts 
of material by weighing or by NMR. The internal standard AUC showed an up to 3-fold 
difference between runs of different samples, depending on the co-injected analyte. 
Biosynthetic divamide A, also quantified by NMR (0.664 mM), was used to assess the 
agreeability between NMR and LC/MS quantification curves. A concentration of 0.624 ± 
0.0363 mM for E. coli-derived divamide A was calculated – a difference of 5.92% less 
than the NMR concentration. The results of LC/MS quantification are summarized in 
Table S3.7. 
3.6.6 Chiral GC/MS. Amino acid standards included Gly and L and D 
configurations of all canonical amino acids as well as L- and D-allo-Ile and Thr. 
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Noncanonical amino acid standards included: L-erythro-Hya (2S,3S), L-threo-Hya 
(2S,3R), D-threo-Hya (2R,3S), LL Lan (2R,6R), meso-DL Lan (2S,6R), LL MeLan 
(2R,3R,6R), DL MeLan (2S,3S,6R), L-allo-MeLan (2R,3S,6R), D-allo-MeLan 
(2S,3R,6R), LL Lal (2S, 9S), and DL Lal (2R, 9S). Peptides (less than 0.1 mg) and 
standards were hydrolyzed in 6 M HCl or 1 M NaOH at 100˚C overnight then dried 
completely under a stream of nitrogen gas followed by high vacuum. Peptide hydrolysate 
and amino acid standards were then esterified with MeOH (200 µl) and acetyl chloride 
(50 µl) in a sealed reaction vial at 100˚C for 1 hour, dried to completion, and finally 
treated with 100 µl each of DCM and PFP-anhydride at 100˚C for 15 min. For the CP-
Chirasil L-Valine column (25 m x 0.25 mm, 0.12 µm), an initial temperature of 80˚C was 
held for 3 min before increasing linearly to 200˚C over 30 min, then holding at 200˚C for 
12 min.  For the Zebron ZB-5MSi Guardian column (30 m x 0.25 mm ID, 0.25 µm), a 
starting temperature of 60˚C was held for 1.5 min before increasing linearly to 250˚C 
over 31.7 min, then holding at 330˚C for 13 min. All samples were prepared at 0.1 mg/ml 
in ethyl acetate and 5 µl injected per run using a split ratio of 2 and helium mobile phase 
gas.  
3.6.7 DNA Extraction. Extraction of DNA from D. molle samples E11-036 and 
E11-037 was complicated by the presence of copious amounts of polysaccharide-rich 
mucus. We utilized a protocol previously adapted from Sokolov for the precipitation of 
polysaccharides found in marine invertebrate slime.21-22 Briefly, tissue was sliced thinly 
and squashed between two aluminum foil sheets, then treated with proteinase K (Qiagen). 
Polysaccharides and proteins were then precipitated with saturated KCl. Additional KCl 
was required beyond what was called for in the original protocol. Samples were 
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centrifuged and an equal volume of isopropanol added to the supernatant. White 
precipitate formed upon incubation at room temperature. The mixture was centrifuged 
again and pellet washed with 70% ethanol. Excess solvent was removed by air drying and 
the pellet resuspended in QBT buffer (QIAGEN). From this point forward, DNA 
extraction followed the standard protocol for the QIAGEN Genomic-tip kit. DNA from 
sample E11-036 was sequenced via Pacific Biosciences (PacBio) single molecule real 
time (SMRT) technology using 5 SMRT cells. Also, an Illumina library was prepared 
using the E11-036 DNA with ~700 bp insert sizes and then sequenced on an Illumina 
Miseq sequencer using a 250 bp paired end run. For D. molle sample E11-037, a 350 bp 
insert size library was prepared and sequenced (100 bp paired end) on an Illumina HiSeq 
2500. 
3.6.8 Assembly of the div cluster. To elucidate the full lanthipeptide cluster, E11-
036 raw Illumina reads were filtered for quality and length (phred score >30 for greater 
than 40 bp) using the windowed adaptive trimming tool Sickle.23 The filtered reads were 
then assembled with the Velvet assembler v. 1.2.09.24 The assembly (kmer size 61) was 
analyzed and produced a contig containing the precursor peptide gene and genes 
homologous to those of the cinnamycin cluster of S. cinnamoneus. In addition, analysis of 
this contig showed unique CDSs, such as a putative methyltransferase. Based on the 
minimum genes required for in vitro cinnamycin biosynthesis by Ökesli et al.,8 a second 
contig with a gene sharing 44% identity to cinorf7, a protein believed to be involved in 
lysinoalanine formation, was included in the divamide cluster. Extensions of the contigs 
using matching reads were then optimized to produce a single contig 17 kbp in length 
containing the entire cluster (12 kbp from precursor gene to the cinorf7 homolog, divLA). 
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This sequence was deposited at GenBank under the accession number KY115608. E11-
037 raw sequencing reads were assembled similarly. Two contigs were identified 
containing genes homologs to those observed in the div gene cluster. One contig 1152 bp 
in length contained the full divA gene and a partial divM sequence, consisting of 111 bp 
of the 3’ end. The second contig, 1655 bp in length, contained additional partial genes, 
consisting of 604 bp of the 5’ end of divX and 603 bp of the 3’ end of divMT, while also 
containing a complete but truncated version of divY, resembling only the 5’ end of E11-
036 divY. By comparison with the divamide A gene cluster, we estimate that a 3144 bp 
gap exists between these two contigs that would account for the remainder of the divM 
and divX genes. The E11-037 partial div cluster was deposited at GenBank under the 
accession number KY115609. 
3.6.9 Construction of pDiv and pRSFDuet-DivMT. Four DNA pieces containing 
portions of the div pathway with putative biosynthetic genes codon-optimized were 
synthesized by Integrated DNA Technologies (IDT) and preassembled into two larger 
pieces by overlapping PCR (Table S3.9). Pieces 1a and 2 were joined via an initial 
reaction with 15 cycles of denaturing (98˚C, 15 s), annealing (62˚C, 30 s), and elongation 
(72˚C, 1 min) using Phusion® DNA polymerase (New England BioLabs). This was 
followed by another 30 cycles of denaturing (98˚C, 15 s), annealing (62˚C, 15 s), and 
elongation (72˚C, 2 min) with primers div1a-fwd and div2-rvs, using the first reaction 
directly as the template (Table S3.10). Similarly, DNA pieces 3 and 1b were joined using 
primers div3-fwd and div1b-rev. The final products were gel purified using Ultrafree-DA 
Centrifugal Filters (EMD Millipore). The vector backbone was obtained by digestion of 
pPat with SacII and KpnI and gel purification of the resulting 4450 bp fragment.9 
 88 
The backbone was transformed into the uracil auxotroph Saccharomyces 
cerevisiae BY4741 along with the PCR-joined 1a-2 and 3-1b DNA pieces for assembly 
by yeast recombination. The resulting colonies, grown on uracil-deficient SD agar, were 
combined and grown overnight in liquid uracil-deficient SD. Plasmid DNA was purified 
from the overnight culture using a QIAprep Spin Miniprep kit (QIAGEN) with protocol 
modifications to enhance cell lysis: the cells were resuspended in buffer P1 with 0.5 mm 
glass beads and mixed by vortex on high for 10 min. Yeast plasmid was transformed into 
DH10ß E. coli and the resulting colonies screened for the presence of div genes by 
sequencing. Additional plasmid was generated from one of the div-positive clones and 
fully sequenced using primers 5 through 15, confirming the desired sequence of pDiv. 
Expression of pDiv in E. coli did not yield any divamide A-like products, so 
modifications were made to the vector to induce production. We had previously observed 
expression of soluble, recombinant DivM only with the native gene sequence (data not 
shown), and reasoned that the codon-optimization of divM might have resulted in poor 
expression or incorrect protein folding, rendering the initial biosynthetic step catalyzed 
by DivM nonfunctional in pDiv.25 The native sequence divM gene was cloned by PCR 
from E11-036 metagenomic DNA using primers intergenic-divM-native-fwd and 
intergenic-divM-native-rvs with Platinum® Taq DNA Polymerase High Fidelity 
(ThermoFisher Scientific) and 35 cycles of denaturation (94˚C, 30 s), annealing (72˚C, 30 
s), and elongation (68˚C, 3 min 30 s) to yield a faint band (Figure S3.6-A). The product 
was diluted 100-fold and amplified by PCR with Phusion® with the same primers by 30 
cycles of denaturation (98˚C, 15 s), annealing (65/72˚C, 30 s), and elongation (72˚C, 3 
min 30 s) and purified using a QIAquick PCR Purification kit (QIAGEN) (Figure S3.6-
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B). pDiv was digested with MluI-HF and AflII to remove the majority of the codon-
optimized divM gene and the resulting 8355 bp band was gel purified using a QIAEX II 
Gel Extraction kit (QIAGEN). The native divM gene and linearized pDiv were assembled 
by yeast homologous recombination as previously described. Yeast lysis was further 
enhanced by incubation with buffer P2 at 55˚C for 10 min after pulverization with glass 
beads by vortex. Plasmids were extracted from individual E. coli colonies transformed 
with yeast DNA and digested with SpeI and NdeI to confirm replacement of the codon-
optimized divM with the native gene, then sequenced with primers 17–22 to verify the 
desired sequence of divM in pDiv2. 
The pDiv3 divamide B expression vector was constructed in two separate phases, 
with replacement of divA in pDiv with a divamide-B encoding divA sequence, followed 
by replacement of codon-optimized divM with the native divM gene. First, pDiv was 
digested with ClaI and NheI restriction enzymes. The product was then gel purified using 
a centrifugal filter as described previously. The linearized vector was recombined with 
synthetic DNA divA-divamideB (IDT; Table S3.9) using yeast as described above. 
Plasmids obtained from pDiv-containing E. coli colonies transformed with extracted 
yeast DNA were sequenced with primer 1, confirming the altered sequence of divA with a 
single noncoding C to G mutation, the position of which is underlined in the sequence 
shown in Table S3.9. The native divM gene was then introduced as described for the 
construction of pDiv2, using the divamide B-encoding pDiv as a template for 
recombination. During the restriction digest of pDiv2, XhoI was used in addition to AflII 
and MluI-HF to cut the codon-optimized divM gene and prevent reinsertion. 
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To construct the methyltransferase expression plasmid pRSFDuet-DivMT, the 
codon-optimized divMT gene was PCR amplified using pDiv as a template with primers 
divMT-MCS1-fwd and divMT-MCS1-rvs, Platinum® Taq Hi-Fi, and 2% DMSO by 30 
cycles of denaturation (94˚C, 30 s), annealing (45.5˚C, 30 s), and elongation (68˚C, 2 
min). The PCR product was purified as described above. Both purified PCR product and 
the empty pRSFDuet vector were then digested with SacI and NotI restriction enzymes. 
Reaction mixtures were heat inactivated and the linearized pRSFDuet was 
dephosphorylated using Antarctic Phosphatase (New England BioLabs). The two pieces 
were then ligated together using T4 DNA ligase (New England BioLabs). The ligation 
reaction was transformed into DH10ß E. coli and the transformed cells plated on LB 
kanamycin selection media. Individual colonies were picked and grown overnight in 
liquid culture. Cells were harvested and plasmids purified using the QIAprep Spin 
Miniprep kit. Plasmids were triple digested with ScaI, MluI, and PstI to verify the 
expected band sizes, and positive plasmids were sequenced for confirmation. 
3.6.10 Expression and purification of the pDiv2-E. coli product. pDiv2 was 
transformed into DH10ß E. coli and six colonies used to inoculate individual wells of a 
24-well plate, each containing LB (6 ml) with ampicillin (50 µg/ml), which was shaken 
overnight at 150 rpm and 30˚C. Wells were combined and 3 ml used to seed each of eight 
2xYT cultures (1L), each containing ampicillin (50 µg/ml) and cysteine hydrochloride 
monohydrate (5 mM) from a freshly prepared, filter-sterilized stock solution (1.66 M), in 
Fernbach flasks (2.8L). These were grown at 30˚C for 48 hours shaking at 150 rpm 
before harvesting cells by centrifugation at 4000 rpm and 4˚C for 30 min and decanting 
the supernatant. Cell pellets were frozen and lyophilized before extracting with DCM and 
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sonicating for 30 min. The DCM extract was removed by centrifugation at 4000 rpm, 4˚C 
for 30 min. Residual DCM was removed by drying the pellets under N2 gas. A second 
extraction with 1:1 acetone:EtOAc followed the same procedure of sonication, 
centrifugation, and drying. The final extraction with 1:1 ACN:H2O was performed 
similarly and in duplicate, with both extractions combined. The organic solvent was 
removed by rotovap and remaining aqueous extract frozen and lyophilized. Typically, 
about 1.2 g of dry extract was obtained per 24 L of culture. Extractions of more than 24 L 
of combined cultures resulted in poor compound recovery due to impaired 
chromatographic resolution. 
Extract was either resuspended in water after weighing or dried directly onto 230-
400 mesh grade 60 silica gel and added atop a silica flash column containing a 10-fold 
excess of silica gel relative to the estimated dry extract weight (i.e. 12 g of silica per 
extract from 24 L of culture), pre-equilibrated with CHCl3. The column was then eluted 
with three column volumes each of CHCl3, EtOAc, 1:1 EtOAc:MeOH, MeOH, and 1:5 
H2O:MeOH. For fractions containing MeOH and H2O, a piece of filter paper was folded 
and held tightly in place at the mouth of the column to filter out any silica particulate co-
eluting with the more polar solvents. The MeOH and 1:5 H2O:MeOH elutions were 
pooled and concentrated to dryness by rotavap and/or lyophilization. Dried silica column 
elutions were resuspended in 30% MeOH in H2O and loaded onto a second column of 4 g 
Bakerbond 40 µm C18 resin per 24 L pooled culture, pre-equilibrated with MeOH, 50% 
MeOH:H2O, and 10% MeOH:H2O. The C18 column was then eluted with five column 
volumes each of 10%, 30%, 50%, and 100% MeOH.  
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 The latter two C18 flash column elutions were pooled and dried, then resuspended 
in no more than 5 ml total volume. HPLC was performed using a Luna 5µ Phenyl-Hexyl 
250 x 10 mm column (Phenomenex) running a 30% ACN/ 70% 0.1% TFA in H2O 
isochratic method at 4 ml/min, with peak A eluting at ~14.3 min and peak B eluting at 
~16.1 min. Retention times tended to increase with repeated injections, and peak shapes 
broadened with injections of higher volume. Organic solvent was removed from HPLC 
fractions by rotovap and the remaining acidic water removed by lyophilization. Typical 
yields by weight for 16 L of culture were ~0.6 mg of peak A and ~1.5 mg of peak B with 
some variability from batch to batch. Both peaks consisted of desmethyl, 
deslysinoalanine divamide, with peak A representing the 20-mer peptide sequence and 
peak B consisting of a mixture of three different extra-proteolytic species. 
3.6.11 Chemical formation of lysinoalanine. HPLC-purified divamide 
intermediates were suspended in 0.1 M Tris buffer pH 10.8 and incubated at 37˚C 
overnight. To remove Tris buffer and salt, the suspension was dried, resuspended in 10% 
MeOH in H2O, and loaded onto a small plug of Fluka C18 resin (90 Å pore size) in a 
Pasteur pipette column pre-equilibrated as described above for the large-scale C18 flash 
column. The plug was eluted with 10% MeOH (2-5 ml), 50% MeOH (1.2 ml), and 100% 
(1.2 ml) MeOH. The 50% and 100% MeOH elutions were pooled. 
The initial confirmation of lysinoalanine formation was carried by desulfurization 
of MeLan residues using in situ Ni2B, prepared from NiCl2 and NaBH4 as described for 
other lanthipeptides.26-30 In our hands, the conditions that worked best were as follows: 
peptide (150 µg, relative to amount estimated by weight) was suspended in of 7:1 
MeOH:H2O (500 µl) with NiCl2 (1-2 mg) pre-dissolved in a 1.5 ml screw-cap reaction 
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vial with stir bar. About a five-fold excess of dry NaBH4 was added directly to the vial, 
which was immediately capped and place in an oil bath at 50˚C for 30 min. The liquid, 
containing black Ni2B precipitate, was transferred to a 1.7 ml microcentrifuge tube and 
centrifuged to remove the majority of precipitate. The supernatant was dried in vacuo and 
desalted on a C18 Pasteur pipette column as described above, washing with 10% MeOH 
in H2O and eluting in 50% and 100% MeOH. The latter two elutions were combined and 
suspended in 75% MeOH and subjected to LC/MS and LC/MS/MS analyses. 
3.6.12 Expression and purification of DivMT. The expression plasmid pRSFDuet-
DivMT was transformed into BL21(DE3) E. coli, and individual colonies were picked to 
inoculate eight wells of a 24-well plate, each containing LB (6 ml) with kanamycin (50 
µg/ml), which was shaken at 150 rpm and 30˚C overnight. The wells were pooled and 
used to inoculate cultures of 2xYT (1 L) media with kanamycin (50 µg/ml) in Fernbach 
flasks (2.8 L), with 5 ml seed culture per flask. Cultures were shaken at 150 rpm and 
30˚C until an OD600 of 0.7 was reached, at which time cells were induced with IPTG (1 
mM). The temperature was then reduced to 18˚C and the cultures allowed to incubate 
overnight. Cells were harvested by centrifugation at 4000 rpm and 4˚C and cell pellets of 
2 L combined culture were frozen. Pellets were thawed on ice and suspended in lysis 
buffer (35 ml; 0.5 M NaCl, 25 mM imidazole, 10% glycerol) with lysozyme (0.4 mg/ml), 
PMSF (1 mM), MgCl2 (10 mM) and DNaseI (<1 mg) freshly added, using a glass stir 
rod. The mixture was sonicated on ice for three cycles of 2 min pulses at 40% amplitude 
(4 s pulse, 10 s delay), then centrifuged at 13 krpm and 4˚C for 30 min. The supernatant 
was filtered using a 0.45 µm syringe filter onto Ni-NTA resin (2 ml; Qiagen) pre-
equilibrated with lysis buffer and allowed to rock at 4˚C for 30 min to equilibrate. The 
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column was rinsed with lysis buffer (100 ml) followed by transition buffer (50 ml; 0.1 M 
NaCl, 25 mM MOPS, 25 mM imidazole, 10% glycerol, pH 8.0) and equilibrated another 
10 min, then eluted with 10 ml each of the following imidazole concentrations, all 
prepared from transition buffer: 50 mM, 100 mM, 200 mM, and 500 mM imidazole. The 
resin was given a 10 min equilibration between each buffer change. SDS-PAGE was used 
to assess the elution time and purity of the 32.6 kDa protein (Figure S3.7). The 200 mM 
elution was then dialyzed in dialysis buffer (1 L; 0.1 M NaCl, 25 mM MOPS, 10% 
glycerol, pH 8.0) at 4˚C. The buffer was exchanged four times within 24 hours, adding 
BME at a final concentration of 5 mM to the first two buffer exchanges only. The 
concentration of the protein prep as determined by UV absorbance at 280 nm using a 
Nanodrop 2000 was 3.77 µM/0.123 mg/ml (MW = 32566.8 Da, e280 (reduced) = 46215). 
3.6.13 Enzymatic N-trimethylation. Desmethyl divamide was suspended to an 
estimated concentration of 2 mg/ml in nanopure water. An analytical scale methylation 
assay was prepared by combining the desmethyl divamide solution (1 µl) with 1 µl of 
each of the following in 20 µl total volume: 0.5 M MOPS (pH 7.5), 50 mM DTT, 100 
mM SAM, and 3.77 µM DivMT. Reactions were mixed and incubated at 37˚C for 1-2 
days using a thermocycler with a heated lid. MeOH was added to 20% of total volume 
and the entire sample subjected to LC/MS analysis. For large-scale DivMT reactions, the 
entire desmethyl divamide solution was used (typically around 300 µl at 2 mg/ml was 
obtained per 24 L batch) and the remaining reagents scaled accordingly. The reaction 
solution was mixed and aliquoted into PCR tube strips, 80 µl per tube, and was incubated 
at 37˚C in a thermocycler for 2 days. All reactions were then pooled and dried in vacuo, 
then desalted using a C18 Pasteur pipette column, eluting this time with 10% MeOH (5-10 
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ml) followed by of 30%, 50%, and 100% MeOH (1.2 ml each). The latter two elutions 
were pooled and subjected to HPLC using a Gemini C6-Phenyl column (150 x 4.60 mm, 
110Å, 3 µ) running an isochratic method of 27% ACN/ 68% 0.1 M NaCl/ 0.1% TFA 
aqueous buffer, yielding divamide A at tR = 18.7 min. Residual extra-proteolytic 
divamide intermediates eluted earlier, at tR = 16.7 min. Organic solvent was removed 
from the collected peak prior to lyophilization. Dried material was suspended in 10% 
MeOH and desalted using a C18 Pasteur pipette column as described before. 
3.6.14 Bioassays. T-cell lymphoid CEM 1a2 tat/rev++ cells are a clone of 
CEMTart tat/rev++ cells that apoptose upon infection with HIV.31 These cells were 
employed for all HIV cytoprotection assays with divamide compounds. Cell lines were 
maintained in RPMI-1640 media supplemented with sodium bicarbonate (2 g/L), fetal 
bovine serum (20%), and antibiotic-antimycotic solution (100 X, GIBCO, Grand Island, 
NY, USA), and were cultivated in 5% CO2 at 37˚C. Assays were run in 96-well round-
bottom plates. Cells (200 µl) were seeded at a concentration of 50,000 cells/ml (12,500 
cells/well) and sample compounds/controls applied in 1 µl DMSO. Azidothymidine 
(AZT) was used as a positive control at a stock concentration of 0.1 and 0.05 mg/ml in 
DMSO. HIV tat/rev- was then applied at an appropriate titer. After a four-day incubation, 
yellow MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; 10 µl, 5 
mg/ml) was added and the plates incubated for 1-2 hours. Plates were then centrifuged, 
the supernatant removed, and DMSO (100 µl) added to solubilize the MTT, now reduced 
and blue in color due to the metabolic activity of live cells. The plate was analyzed by 
plate reader at 590 nm and the results tabulated. 
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To best compare sample responses between HIV infected and uninfected states, 
data were first normalized to the uninfected control, adjusted by the normalized HIV 
infected control response, and then scaled for ease of comparison. In this way, data could 
be interpreted as the percent cell survival relative to HIV infected cells. To obtain the 
normalized sample response, SN, equation 3.1 was used:  
 𝑺𝑵 = 𝑺𝒂𝒗𝒈'𝑩𝒂𝒗𝒈𝑼𝒂𝒗𝒈  (3.1) 
Variables represent average assay response values from three similarly treated wells of 
sample (S), blank (B), and uninfected control (U). Infected cells with and without AZT 
treatment were also normalized to obtain AN and IN, respectively. The highest AZT 
response of the two concentrations employed was used. Normalized data were then 
scaled the fit a range of 0-100, with the 0 and 100 % thresholds representing the infected 
and uninfected states, respectively. The scaling factor, s, was calculated using equation 
3.2, while sample and AZT control data were scaled using equation 3.3:  
 𝒔 = 𝟏𝟎𝟎𝑼𝑵'𝑰𝑵 (3.2) 
 𝑺𝑺 = 𝑺𝑵 − 𝑰𝑵 𝒔 (3.3) 
Under these conditions, the scaled uninfected control response US was equal to 100 % 
relative survival.  
Dose-response curves were generated and fit using KaleidaGraph: 
 𝒚 = 𝑫𝟏 + 𝑨𝟏'𝑫𝟏𝟏3𝟏𝟎 𝒙5𝒍𝒐𝒈𝑪𝟏 𝑩𝟏 + 𝑫𝟐 + 𝑨𝟐'𝑫𝟐𝟏3𝟏𝟎 𝒙5𝒍𝒐𝒈𝑪𝟐 𝑩𝟐  (3.4) 
For a typical sigmoidal curve, A and D represent y-min and -max values, respectively, 
while x = log concentration, C is the IC50, and B the Hill coefficient. Because equation 
3.4 combines two unrelated dose-dependent effects, A and D values do not accurately 
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reflect y-min and -max values. B and C, however, are independent of y, the percent 
relative survival. C1 and C2 provide the IC50 and CC50 values, while B1 and B2 represent 
the steepness of their respective curve. Some sample curves showed a dip in the 
cytoprotection curve and could not be fit using the above model (Figure 3.12). For these 
compounds, IC50 and CC50 values were estimated by eye (Figure 3.3-A). 
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Figure 3.1. Discovery of the divamides from Didemnum molle. A) The divamide-
producing Didemnum molle tunicates E11-036 (left) and E11-037 (right) were found 
living side-by-side in the Eastern Fields of Papua New Guinea, approximately 5-10 m 
underwater. The two tunicates exhibit distinct morphologies that may represent 
genetically distinct species.32 B) The chemical structure of the anti-HIV lanthipeptide 
divamide A, produced by E11-036, elucidated by NMR (Figure S3.2; Tables S3.1, S3.2) 
and chiral GC/MS (Figure S3.3; Table S3.3). C) Divamides A-C display an identical 
scaffold to cinnamcyin, incorporating lanthionine (yellow), lysinoalanine (red), and ß-
hydroxyaspartic acid (blue) in the same sequential positions, but include an additional N-
terminal N-trimethylated residue (green). Differences in sequence from divamide A are 
shown in red text. D) The E11-036 div biosynthetic gene cluster (divA; top) exhibits 
nearly 100% identity with the partial E11-037 div gene cluster (divB; bottom), with the 




Figure 3.2. Synthesis of divamide A. The semi-in vivo synthesis of divamide A (left 
column) involves in vivo, chemical, and enzymatic steps. A) The divamide A expression 
plasmid, pDiv2, enables in vivo expression of a divamide intermediate that incorporates 
three MeLan residues, Hya, and dehydroalanine (Dha) by DH10ß E. coli (Step 1). B) The 
desmethyl, deslysinoalanine intermediate, purified from E. coli (m/z = 989.8), is 
incubated in base to induce formation of Lal (Step 2), the desmethyl divamide A product 
of which is the substrate of SAM-dependent N-trimethyltransferase DivMT (Step 3). C) 
The putative native biosynthetic route of divamide A requires DivM, DivX, proteolysis 
by an endogenous protease, and DivMT. DivLA may be involved in Lal formation in the 
cyanobacterial tunicate endosymbiont Prochloron didemni.8 D) Comparison of tunicate-
derived (top) and synthetic divamide A (bottom) by mass spectrometry (m/z = 1010.8) 





Figure 3.3. Biological activity of the divamides. Dose-response curves were generated 
for all divamide species generated alongside cinnamycin using the same cytoprotection 
assay used in the initial screening of tunicate extracts. A) Nine compounds were assayed 
in total. IC50 values correspond to anti-HIV activity, while CC50 values reflect 
cytotoxicity. For some compounds, values were estimated by eye (~) due the difficulties 
associated with fitting the resulting atypical curves (samples 5-7). A dash indicates the 
absence of that particular biological response. B) The dose-response curve of each 
compound assayed is shown as a bar graph. I = response level of infected cells, U = 
response level of uninfected cells, A= response level of AZT. Dashed red lines represent 
the AZT response ± one standard deviation. Boxed compound numbers represent 
synthetic species. The concentrations of each sample follow the top values shown in the 
key, corresponding to a 1:3 dilution series, while those specifically indicated in the table 
with an * follow the bottom values, corresponding to a 1:4 dilution series. C) Individual 
dose-response curves were fit with the sum of two four-parameter IC50 equations to 
simultaneously determine the IC50 and CC50 values. A wider therapeutic window was 
observed for the divamide A methyl ester (2) than for divamide A (3), while cinnamycin 








Figure S3.1. Anti-HIV screen of tunicate extracts. All fractions generated as described in 
the supplementary methods were screened in an HIV cytoprotection assay to identify 
active anti-HIV agents. The number of cells living four days after infection with HIV is 
represented by 0% relative survival, while 100% relative survival indicates uninfected 
cells. The average assay response of the positive control, AZT, is shown as a red line, 
with dashed lines representing the average response ± the standard deviation. Each point 
represents an individual fraction at a specific concentration. Fractions included both 
crude extracts and HPLC-purified compounds. A portion of fractions derived from E11-
036 showed cytoprotection comparable to the effects elicited by AZT, while fractions 
from E11-037 and solvent controls did not display anti-HIV activity. Taking into account 
the assay results of all fractions from a given source, a student’s t-test showed statistical 
significance between E11-036 and both control (*; p-value = 0.00362) and E11-037 (**; 
p-value = 0.0177) fractions. The large number of E11-036 data points represent multiple 
rounds of fractionation and repeats of assays, inflating the population size relative to the 
other two groups. This inflation should skew the t-test in favor of rejecting statistical 
significance, yet the data show significance nonetheless, indicating authentic anti-HIV 







Figure S3.2. Natural divamide A NMR data. 600 MHz NMR data collected in D2O 
include: A) 1H spectrum, B) gradient correlation spectroscopy (gCOSY) spectrum, C) z-
filter total correlation spectroscopy (zTOCSY) spectrum, D) nuclear Overhauser effect 
spectroscopy (NOESY) spectrum, E) gradient heteronuclear single quantum coherence 
(gHSQC) spectrum, and F) gradient heteronuclear multiple bond correlation (gHMBC) 
spectrum. 600 MHz data collected in 90% H2O/ 10% D2O include: G) jump and return 
(1-1) decoupling in the presence of scalar interactions (DIPSI) spectrum and H) 1-1 
NOESY spectrum. NMR data collected in 70% CD3OH/ 30% H2O/ 0.1% TFA at 36˚C 
include: I) 500 MHz 13C spectrum, J) 900 MHz 1-1 1H spectrum, K) 900 MHz 1-1 
NOESY spectrum, L) 900 MHz 1-1 DIPSI spectrum, M) 900 MHz gradient carbon 







































































































































Figure S3.3. Chiral GC/MS chromatograms. Divamide A stereochemistry was 
determined by comparing GC/MS fragmentation patterns and retention times of acid 
hydrolyzed and chemically derivatized peptide with amino acid standards using a chiral 
stationary phase. A) Selected Ion Mode (SIM) chromatogram of MeLan showing 
alignment of the MeLan peak in divamide A with the DL-MeLan standard. B) SIM 
chromatogram of Hya showing alignment of the divamide A Hya peak with L-erythro-
Hya. C) SIM chromatogram of Lal showing alignment of the divamide A Lal peak with 
LL-Lal using an achiral stationary phase. 
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Figure S3.4. Natural divamide B NMR data. 600 MHz NMR spectra collected in 70% 
CD3OD/ 30% D2O/ 0.1% TFA at 36˚C include: A) 1H spectrum, B) gCOSY spectrum, C) 
zTOCSY spectrum, D) NOESY spectrum, E) gHSQC spectrum, and F) gHMBC 
spectrum. Data collected in 70% CD3OH/ 30% H2O/ 0.1% TFA include: G) 1-1 1H 



































































































Figure S3.5. Natural divamide C NMR data. 600 MHz NMR spectra collected in 70% 
CD3OD/ 30% D2O/ 0.1% TFA at 36˚C include: A) 1H spectrum, B) gCOSY spectrum, C) 
zTOCSY spectrum, D) NOESY spectrum, and E) gHSQC spectrum. F) Data collected in 
70% CD3OH/ 30% H2O/ 0.1% TFA include: 1-1 1H spectrum, G) 11-DIPSI spectrum, H) 




















































































Figure S3.6. Native divM PCR amplification. A) Amplification of the native divM gene 
from E11-036 metagenomic DNA by PCR resulted in a faint band of the anticipated 
length. B) The product of the first PCR amplification was used as a template for 
amplification cycle to generate additional divM for the replacement of the codon-




Figure S3.7. Expression and purification of DivMT. DivMT was purified on Ni-NTA 
fractions from the cell lysate of pRSFDuet-DivMT-expressing E. coli BL21(DE3). The 
Ni-NTA fractions were analyzed by SDS-PAGE. P = pellet, L = filtered cell lysate 
(supernatant), FT = Ni-NTA column flowthrough, W = column wash with lysis buffer, T 
= column wash with transition buffer, E = elutions of increasing imidazole concentration 
in transition buffer (1 = 50 mM, 2 = 100 mM, 3 = 200 mM, 4 = 500 mM imidazole). A 
band of the expected molecular weight for His6-DivMT was observed in E3, and this 














Figure S3.8. Mass spectra of divamide expression in E. coli. Organic extracts of E. coli 
expressing pDiv2 (A) and pDiv3 (B) were analyzed by LC/MS. In each spectrum, the 
primary expression product observed is the desLal divamide derivative (m/z 989.9 and 
944.8 for desLal divamide A and B, respectively), but extra-proteolytic species were also 











Figure S3.9. Quantitative NMR standard curves. Standard curves for the quantification 
of low abundance materials were generated by NMR using a dilution series of L-Trp in 
H2O, the concentration of which was determined by UV-absorbance (e280, Trp = 5170.9 
nm-1). The absolute integral was plotted as a function of concentration using three 
different proton signals aromatic signals: HE3 (A), HZ3 (B), and methylene HB2 (C). The 
linear equations generated were used to determine yields of divamide analytes of 
















Figure S3.10. Quantitative LC/MS standard curve. A standard curve for the 
quantification of divamide intermediates was generated using a dilution series of 
synthetic desmethyl divamide A, previously quantified by NMR. The resulting linear 
equation was used to determine concentrations of divamide analytes and estimate relative 
ratios of compound mixtures, such as those obtained from expression in E. coli. 















Figure S3.11. Synthetic divamide A NMR data. NMR spectra of E. coli-derived 
divamide A intermediates obtained in 70% CD3OH/ 30% H2O/ 0.1% TFA include the 
following: A) 600 MHz 1-1 1H spectrum, B) 11-NOESY spectrum, C-E) gCHSQC 
spectra of the aliphatic (C), alpha carbon (D), and aromatic (E) regions of desmethyl 
deslysinoalanine divamide A. NMR spectra of synthetic divamide A obtained in 70% 
CD3OH/ 30% H2O/ 0.1% TFA include: F) 500 MHz 1-1 1H spectrum, G) 11-NOESY 





























































































Figure S3.12. HIV cytoprotection dose-response curves. All divamide species available 
were investigated. U = uninfected, I = infected, and A = AZT response. A) Compounds 
for which curves could be fit with equation 3.4 or a single four-parameter IC50 equation. 
B) HIV cytoprotective compounds for which the curve could not be fit due to an 
abnormal shape characterized by a dip in response at middle concentrations. C) HIV 
inactive compounds, two of which still display cytotoxicity (deslysinoalanine divamide A 


















Figure S3.13. Detection of N-trimethylation by Hoffmann elimination. A) The Hoffman 
elimination of trimethylamine from a quaternary N-trimethylamine results in a net loss of 
60 Da and the elimination of a positive charge. B) This characteristic was observed for N-
trimethylglutamate-containing lanthipeptides divamide A (i), B (ii), and C (iii) by LC/MS 












Figure S3.14. Divamide-like lanthipeptide gene clusters. All divamide-like lanthipeptide 
gene clusters that could be identified by BLAST search of div pathway genes are shown. 
They occur only in cyanobacteria (A) and actinobactera (B). Cyanobacteria may contain 
multiple lanthipeptide clusters within a single genome or multiple lanA precursor proteins 
in a single cluster, suggesting multiple products are produced from a single strain. Each 
pathway maintains the genes responsible for introducing conserved modifications, 
including Lan/MeLan and Hya. Most also contain divLA homologs, but this gene does 
not appear to be 100% conserved across all pathways. Some cyanobacterial pathways 
have incorporated unique modifying enzymes. A methyltransferase bearing no 
resemblance to DivMT can be found in the first pathway from Cylindrospermum stagnale 
PCC7417 (“orf1”). The recently reported oscillamycin is the product of the second 
cluster from Oscillatoria sp. PCC 10802 and contains hydroxyproline, presumably 
introduced by the putative proline hydroxylase located in the first cluster (“orf”).33 Many 
of the actinobacterial cluster strongly resemble that of cinnamycin, containing 
cinnamycin regulatory gene homologs, while cinnamycin B, recently reported from 
Actinomadura atramentaria NRBC 14695 (the cluster described here was identified by 
BLAST search from Actinomadura atramentaria DSM 43919),34 includes only the 
essential divamide-like biosynthetic genes. Thus, the div family lanthipeptides display 























































































































































































































Table S3.1. Summary of NMR data for divamides A and B. Divamide A data were 
collected in either D2O and 90% H2O/ 10% D2O at 600 MHz (a), or 70 % CD3OD/ 30% 
D2O/ 0.1% TFA and 70 % CD3OH/ 30% H2O/ 0.1% TFA at 36˚C and 900 MHz (b). 
Divamide B data was collected in 70 % CD3OH/ 30% H2O/ 0.1% TFA at 36˚C and 600 
MHz (c). Unassigned carbonyl chemical shifts observed by 13C NMR spectroscopy in 70 
% CD3OH/ 30% H2O/ 0.1% TFA are included (Figure S3.2-I). 22 total carbonyl signals 
were detected. 
	
divamide A divamide A a divamide A b divamide B c divamide B 
Residue Position dC dH dC dH dC dH Position Residue 
Glu1 NMe 53.5 3.27 53.0 3.25 52.6 3.23 NMe Glu1 
 A 74.1 4.16 74.0 4.15 73.6 4.17 A  
 B 22.7 2.43 22.6 2.37 22.1 2.38 B  
   2.26  2.20  2.22   
 G 30.1 2.67 29.8 2.59 29.4 2.61 G  
   2.54  2.47  2.51   
 D 176.8  –  –  D  
 CO –  –  –  CO  
Cys2 N  9.16  9.02  9.03 N Cys2 
 A 53.6 4.93 – 4.85 52.9 4.86 A  
 B 32.5 3.57 32.6 3.47 32.0 3.46 B  
   3.17  3.12  3.15   
 CO –  –  –  CO  
Ala3 N  8.33  8.33  8.34 N Ala3 
 A 50.1 4.65 49.9 4.64 49.4 4.67 A  
 B 18.8 1.41 18.6 1.35 18.8 1.38 B  
 CO 175.0  176.3  174.4  CO  
Ser4 N  8.40  8.30  8.31 N Ser4 
 A 55.4 5.37 55.4 5.39 54.9 5.38 A  
 B 65.5 4.09 65.4 4.00 64.7 4.02 B  
   3.85  3.75  3.79   
 CO –  –  –  CO  
Thr5 N  8.32  8.23  8.24 N Thr5 
 A 57.6 5.04 57.5 5.05 57.0 5.08 A  
 B 52.4 3.21 53.0 3.07 – 3.10 B  
 G 23.4 1.43 23.2 1.40 22.8 1.42 G  
 CO –  –  –  CO  
Cys6 N  9.07  9.11  9.31 N Cys6 
 A 55.9 4.49 56.0 4.50 55.6 4.54 A  
 B 37.6 2.67 37.8 2.67 – 2.82 B  
   2.44  2.52  2.73   
 CO –  –  –  CO  
Ser7 N  –  11.36  10.4 N Ser7 
 A 51.9 4.79 – 4.85 50.9 5.03 A  
 B 47.5 3.02 47.7 2.99 47.8 3.50 B  
   2.88       
 CO –  –  –  CO  
Phe8 N  7.54  7.68  7.92 N Ser8 
 A 54.3 5.06 54.5 4.92 55.5 4.62 A  
 B 40.0 3.32 39.8 3.18 62.3 3.84 B  
   2.97  2.93     
 G 136.5  –      
 D 130.9 7.20 130.7 7.15     
 E 129.8 7.35 129.6 7.24     
 Z 128.3 7.33 128.1 7.22     
 CO 173.8  –  –  CO  
Gly9 N  8.81    8.44 N Gly9 
 A 43.0 4.40 42.9 8.60 – 4.37 A  
   3.95  4.27  4.00   
 CO 172.5  – 3.75 –  CO  
Ile10 N  8.33  8.15   N Pro10 
 A 59.7 4.45 59.5 4.35 61.7 4.51 A  
 B 37.6 2.16 37.3 2.07 – 2.19 B  
 G1 16.4 0.926 15.5 0.883  2.09   
 G2 25.0 1.30 25.0 1.35 – 2.10 G  
   1.20 14.3 1.19  1.97   
 D 15.5 0.907  0.876 46.8 3.66 D  




Table S3.1 Continued 
divamide A divamide A a divamide A b divamide B c divamide B 
Residue Position dC dH dC Residue Position dC dH dC 
Val11 N  8.41  8.26  8.27 N Ile11 
 A 64.4 4.00 64.0 3.94 60.4 4.15 A  
 B 29.9 2.32 29.9 2.28 35.6 2.13 B  
 G 20.5 1.05 20.0 1.01 15.7 0.966 G1  
      25.6 1.54 G2  
       1.24   
      8.8 0.85 D  
 CO 177.1  –  –  CO  
Thr12 N  8.48  8.28  8.42 N Thr12 
 A 62.8 4.36 62.5 4.37 61.3 4.54 A  
 B 50.5 3.35 50.0 3.38 – 3.50 B  
 G 20.7 0.972 20.3 1.00 17.5 1.16 G  
 CO –  –  –  CO  
Ile13 N  8.05  7.68  7.69 N Ala13 
 A 61.1 4.28 60.5 4.35 50.9 4.54 A  
 B 38.7 1.74 38.4 1.78 18.4 1.38 B  
 G1 19.4 0.912 19.1 0.885     
 G2 25.9 1.51 25.6 1.49     
   1.08  1.06     
 D 10.6 0.838 10.9 0.817     
 CO 174.7  –  174.0  CO  
Val14 N  9.20  8.46  7.91 N Ile14 
 A 61.6 3.85 60.9 3.91 57.4 4.22 A  
 B 30.4 2.04 30.6 2.03 36.7 1.88 B  
 G1 20.3 1.04 20.0 0.980 14.5 0.866 G1  
 G2 12.5 0.915 11.8 0.883 25.3 1.54 G2  
       1.24   
      9.52 0.859 D  
 CO –  –  –  CO  
Cys15 N  8.98  8.87  9.01 N Cys15 
 A 58.1 3.53 57.8 3.55 57.4 3.62 A  
 B 35.0 1.98 35.3 2.93 – 2.99 B  
     2.84  2.85   
 CO 174.3  –  –  CO  
Hya16 N  7.50  7.37  7.55 N Hya16 
 A 59.8 4.96 58.9 5.03 57.9 5.01 A  
 B 73.1 4.74 – – 72.3 4.58 B  
 G –  –  –  G  
 CO –  –  –  CO  
Gly17 N  7.52  7.45  7.59 N Gly17 
 A 44.1 4.53 43.9 4.42 43.0 4.39 A  
   4.08  4.02  4.03   
 CO 169.5  –  –  CO  
Thr18 N  8.28  8.20  8.22 N Thr18 
 A 57.8 5.10 57.7 5.11 57.5 5.11 A  
 B 69.3 4.15 69.0 4.00 68.3 4.01 B  
 G 18.5 1.20 17.9 1.14 19.4 1.14 G  
 CO –  –  –  CO  
Thr19 N  7.93  7.80  7.87 N Thr19 
 A 60.8 4.45 60.4 4.41 59.7 4.43 A  
 B 41.9 3.62 42.0 3.56 41.7 3.62 B  
 G 21.3 1.40 20.9 1.35 20.3 1.34 G  
 CO –  –  –  CO  
Lys20 N  8.82  8.74  8.72 N Lys20 
 A 55.7 4.05 54.9 4.06 53.8 4.12 A  
 B 30.8 2.00 30.6 1.95 29.5 1.97 B  
   1.35  1.38  1.51   
 G 23.3 1.37 23.1 1.32 – 1.38 G  
   1.28    1.37   
 D 26.5 1.70 26.3 1.70 28.8 1.75 D  
       1.34   
 E 48.5 2.86 48.2 2.81 47.9 2.94 E  
   2.72  2.74     
 CO –  –  –  CO  
Unassigned CO chemical shifts for divamide Ab: 176.0, 175.7, 175.1, 174.8, 174.7, 174.5, 174.1, 174.0, 173.8, 173.7, 173.5, 173.3, 





Table S3.2. NOE and HMBC correlations for divamides A and B. Correlations observed 
in NOESY and HMBC NMR spectra for divamides A (in D2O or 90% H2O/ 10% D2O) 
and B (in 70% CD3OD/ 30% D2O/ 0.1 % TFA or 70% CD3OH/ 30% H2O/ 0.1 % TFA) 
are summarized. 
	
















































































































































Table S3.2 Continued 










































































































































































Table S3.3. Amino acid standards for chiral GC/MS. Standards were used to determine 
divamide A stereocenter configurations by comparative analysis via chiral GC/MS. Lal 
could not be detected using the chiral stationary phase, but diastereomers could be 
resolved using an achiral column (*). Fragmentation patterns of noncanonical amino 
acids, including Hya (a),36 MeLan (b),37 and Lal (c),38 were previously known. 
	
Standard RT (min) Fragment ions (m/z) 
L-Ala 3.748 281.1, 190.2, 119.1 
L-Val 4.967 218.2, 203.2, 119.1 
D-Thr 5.47 381.1, 366.1, 235.2, 230.2, 202.2, 119.1 
Gly 5.495 176.2, 119.1 
L-Thr 5.935 381.1, 366.1, 235.2, 230.2, 202.2, 119.1 
D-allo-Ile 6.005 235.2, 232.2, 203.2, 119.1 
L-allo-Ile 6.646 235.2, 232.2, 203.2, 119.1 
L-Ile 7.011 235.2, 232.2, 203.2, 119.1 
D-allo-Thr 9.033 381.1, 366.1, 235.2, 230.2, 202.2, 119.1 
D-Ser 9.058 352.1, 247.2, 215.2, 188.2, 160.2, 119.1, 100.2 
L-Ser 9.596 352.1, 247.2, 215.2, 188.2, 160.2, 119.1, 100.2 
D-threo-Hya a 9.613 246.0, 214.0, 154.0, 119.1 
L-allo-Thr 9.841 381.1, 366.1, 235.2, 230.2, 202.2, 119.1 
L-threo-Hya a 10.514 246.0, 214.0, 154.0, 119.1 
D-Asp 11.097 248.2, 228.2, 216.2, 206.2, 119.1 
L-Asp 11.382 248.2, 228.2, 216.2, 206.2, 119.1 
L-erythro-Hya a 12.3 246.0, 214.0, 154.0, 119.1 
D-Glu 15.559 262.1, 230.2, 202.2, 119.1 
L-Glu 16.265 262.1, 230.2, 202.2, 119.1 
D-Phe 17.063 266.1, 162.2, 131.1, 119.2, 103.2, 91.2, 77.2 
L-Phe 17.71 266.1, 162.2, 131.1, 119.2, 103.2, 91.2, 77.2 
L-Lys 27.317 420.1, 230.2, 176.2, 119.1 
DL-MeLan b 29.138 379.1, 262.1, 248.0, 234.1, 202.1, 188.1, 119.1 
LL-MeLan b 29.399 379.1, 262.1, 248.0, 234.1, 202.1, 188.1, 119.1 
L-allo-MeLan b 29.779 379.1, 262.1, 248.0, 234.1, 202.1, 188.1, 119.1 
D-allo-MeLan b 29.959 379.1, 262.1, 248.0, 234.1, 202.1, 188.1, 119.1 
LL-Lal *, c 28.261 640.2, 465.2, 405.1, 230.1, 190.1, 119.0, 67.0 





Table S3.4. Gene annotations for the divA biosynthetic gene cluster. CDSs of the divA 
biosynthetic gene cluster (GenBank: KY115608) from the E11-036 metagenome are 
listed alongside their most similar BLAST search results. Conserved protein domains and 
biochemical characterizations are included. 
	









-2 369 WP_007353413.1 54 hypothetical protein (Kamptonema) none not characterized 




none not characterized 
divA 276 WP_017718744.1 63 
hypothetical protein 
(Oscillatoria sp. PCC 
10802) 
none precursor gene 
divM 3255 WP_017718743.1 70 
hypothetical protein 






divX 918 WP_017718741.1 58 
hypothetical protein 






divY 780 WP_038094010.1 45 hypothetical protein (Tolypothrix bouteillei) Het-C (pfam07217) not characterized 






divT 1941 WP_008178015.1 64 
ABC transporter permease 







divU 858 WP_069349017.1 63 hypothetical protein (Scytonema millei) 
FGE-sulfatase 
(pfam03781) not characterized 
divLA 351 WP_008178005.1 53 
hypothetical protein 
(Oscillatoria sp. PCC 
10802) 
none 
putative role in 
Lal formation 
(Okesli, 2011) 





FHA (pfam00498) not characterized 
+2 1905 WP_015185269.1 54 
serine/threonine protein 
phosphatase (Microcoleus 
sp. PCC 7113) 
PP2Cc (cd00143) not characterized 
 
 
Table S3.5. Comparison of the partial divB biosynthetic gene cluster to divA. CDSs of the 
partial divB biosynthetic gene cluster (GenBank: KY115609) from the E11-037 
metagenome are compared with their respective divA homologues. 
 
Gene ID Length (bp) Coverage with corresponding divA gene 
% ID to corresponding 
divA gene 
-1 286 (partial) 88 100 
divA 276 100 93 
divM 111 (partial) 3 100 
divX 604 (partial) 66 100 
divY 272 37 86 





Table S3.6. Summary of quantitative NMR experiments. All samples were suspended in 
120 µl of D2O. A known concentration of L-Tyr was used to assess the quality of the L-
Trp standard curves. A difference of 7.6% was calculated for the NMR-determined 
concentration relative to the UV-determined concentration. All divamide samples were 
quantified with (top row) and without (bottom row) inclusion of the methyl region 
integral because this integral accounts for a large number of protons, which may reduce 
the accuracy of integration. Desmethyl divamide A, divamide B, and divamide C were 
quantified using integrals for only two proton signals such that numbers obtained with 
exclusion of methyl integrals represent a single integral. Yields were calculated from the 






Table S3.7. Summary of quantitative LC/MS experiments. Concentrations were 
determined from the standard curve of desmethyl divamide A shown in Figure S3.9. For 
mixtures of compounds, the concentrations in mg/ml were calculated based on individual 
molecular weights before adding together. The concentration of E. coli divamide A 






Table S3.8. Divamide-like masses observed from Didemnum molle extracts. Ions 
observed by LC/MS resembled those of characterized divamides in m/z and isotope 
distribution. While some masses appear to be derivatives of the characterized divamides 
A-C, others likely reflect alternative amino acid sequences at various stages of post-
translational modification. 
	
Observed m/z (z = 2) Source ID 
1010.9 E11-036 divamide A 
880.5 E11-037 ? 
893.5 E11-037	 ? 
900.5 E11-037	 ? 
935.9 E11-037	 ? 
942.9 E11-037	 ? 
944.9 E11-037	 divamide B - 3 x Me 
951.9 E11-037	 divamide B - 2 x Me 
953.9 E11-037	 ? 
958.9 E11-037	 divamide B - 1 x Me 
965.9 E11-037	 divamide B 
973.9 E11-037	 divamide B + 1 x O 
974.9 E11-037	 ? 
982.9 E11-037	 ? 
1010.5 E11-037	 ? 
1016.5 E11-037	 ? 
1018.5 E11-037	 ? 
1025.5 E11-037	 ? 
1026.5 E11-037	 ? 
1027.5 E11-037	 ? 
1039.5 E11-037	 divamide C 
1047.5 E11-037	 divamide C + 1 x O 
1053.9 E11-037	 ? 
1089.5 E11-037	 ? 
1091.9 E11-037	 ? 
1098.9 E11-037	 ? 
1099.9 E11-037	 ? 
1127.6 E11-037	 ? 
1146.0 E11-037	 ? 
1185.5 E11-037	 ? 





Table S3.9. DNA sequences used to construct pDiv. gBlocks purchased from Integrated 
DNA Technologies. 
	



































































































Table S3.10. PCR and sequencing primers. Primers used in the construction and 
sequencing of pDiv, pDiv2, and pRSFDuet-divMT. 
	
# Primer name Sequence (5’-3’) 
1 div1a-fwd CTCGTATGTTGTGTGGAATTGTG 
2 div2-rev CGGTTCTCGGTGCTCAG 
3 div3-fwd TAGACAATGCCAAACGCC 
4 div1b-rev CGGGTAAGCCGCGAC 
5 divM-203-fwd CGATCGCCAGCACAAC 
6 divM-1424-rev CCAGTCCAGCATGGCTG 
7 divM-2818-fwd GCAGGCCGTCAGGG 
8 divX-650-rev AGCCCGGCTGGGTTTC 
9 divX-580-fwd GAGACAGAGCTGCGCTTTAG 
10 divMT-79-rev CAATGAAGAAGGCGTTCAG 
11 divMT-20-fwd CGTTCGAACTGAAAGCCTATG 
12 divM-203-fwd CGATCGCCAGCACAAC 
13 divM-1977-f CTTAGCCGCCGAAAGC 
14 divX-461-f TGCCTAGCCCTCAGCC 
15 divHypo-780-f CGCATCCGTAATTAATCCC 




18 divMp-fwd GTGGAACTGCTGAACAAC 
19 divM-non-optimized-pET16b-Gibson-fwd cgaaggtcgtcatATGCTTGATGATTTTTCTCTCC 
20 divM-native-fwd-1 CTTTAGCCTGGGCTCTTG 
21 divM-native-fwd-2 GGACAGTGCTTGATTCAG 
22 divM-native-rvs-4 CTTCATCAAATTGGGTCG 
23 divMT-MCS1-fwd TTCGAGCTCGATGGAAAATAATAATTATCCGTTCG 
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4.1. An integrated approach for natural product discovery 
 
Natural products provide a significant source of inspiration for drug design and 
are, in some instances, drugs themselves.1 The drug design process, however, relies on 
the discovery of novel chemical entities and the identification of drug leads targeting 
unique biological processes. The discovery of novel chemical scaffolds has dwindled 
since the field’s infancy. Particular locations or environments have been sampled 
redundantly such that more ubiquitous and copious chemistry, the “low-hanging fruit”, is 
commonly re-isolated. However, a vast ocean of uncharted chemistry, or chemical “dark 
matter”, exists in nature, waiting to be discovered but impossible to access using 
traditional approaches. Modern strategies employ genome mining to identify putative 
biosynthetic clusters based on comparison to known biosynthetic machinery. This has the 
advantage of providing the blueprints for biosynthesis, but in the absence of structural or 
biological characterization it cannot predict the therapeutic value of a pathway.  
Here, I have described two instances in which structural and genomic approaches 
were integrated for the discovery and supply of therapeutically relevant natural products. 
In both cases, structural features were used to predict specific aspects of the biosynthesis 
that, at least for the divamides, has led to pathway discovery. The adociasulfate example 
 162 
shows how an integrated approach can be used to begin to recognize pathways that may 
not fall within any typical natural product pathway organization or, as for the divamides, 
can be used to gain access to novel chemistry from small samples. Such a strategy could 
be applied to even smaller samples by utilizing small-scale, high-throughput LC-MS-
SPE-NMR screening to collect structural data for very small amounts of material.2-3 
Additionally, hundreds of natural products with known biological activities exist for 
which total synthesis is exceedingly difficult or impossible. A biosynthetic analysis of 
these compounds followed by genomic or metagenomic interrogation may reveal novel 
routes for natural product construction. Unique pathways interwoven with primary 
metabolism may exist, or even cooperative pathways in which multiple organisms take 
part in the production of a compound. Such instances would not be recognized without 
taking into account both structure and genetics. 
To date, natural product discovery has relied heavily on obtaining large quantities 
of material for structural and biological characterization, and has recently become 
overwhelmed with expansive genomic and metabolomic data. The union of the two 
approaches can result in a targeted discovery process, providing a compass with which 
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